<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4770723</article-id><article-id pub-id-type="pmid">26416427</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic>MYC</italic>-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Qingqing</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Medeiros</surname><given-names>L. Jeffrey</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Xiaolu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Ken H.</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China</aff><aff id="A2"><sup>2</sup> Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</aff><aff id="A3"><sup>3</sup> The University of Texas School of Medicine, Graduate School of Biomedical Sciences, Houston, Texas, USA</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Ken H. Young,</italic><email>khyoung@mdanderson.org</email></corresp></author-notes><pub-date pub-type="collection"><day>17</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>9</month><year>2015</year></pub-date><volume>6</volume><issue>36</issue><fpage>38591</fpage><lpage>38616</lpage><history><date date-type="received"><day>17</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>4</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Cai et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><italic>MYC</italic>, a potent oncogene located at chromosome locus 8q24.21, was identified initially by its involvement in Burkitt lymphoma with t(8;14)(q24;q32). <italic>MYC</italic> encodes a helix-loop-helix transcription factor that accentuates many cellular functions including proliferation, growth and apoptosis. <italic>MYC</italic> alterations also have been identified in other mature B-cell neoplasms and are associated with aggressive clinical behavior. There are several regulatory factors and dysregulated signaling that lead to <italic>MYC</italic> up-regulation in B-cell lymphomas. One typical example is the failure of physiological repressors such as Bcl6 or BLIMP1 to suppress <italic>MYC</italic> over-expression. In addition, <italic>MYC</italic> alterations are often developed concurrently with other genetic alterations that counteract the proapoptotic function of <italic>MYC</italic>. In this review, we discuss the physiologic function of <italic>MYC</italic> and the role that <italic>MYC</italic> likely plays in the pathogenesis of B-cell lymphomas. We also summarize the role <italic>MYC</italic> plays in the diagnosis, prognostication and various strategies to detect <italic>MYC</italic> rearrangement and expression.</p></abstract><kwd-group><kwd>MYC</kwd><kwd>Myc protein</kwd><kwd>translocation</kwd><kwd>microRNA</kwd><kwd>lymphoma</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p><italic>MYC</italic> was recognized initially because of its involvement in t(8;14)(q24;q32) in Burkitt lymphoma, in which <italic>MYC</italic> at 8q24.21 is juxtaposed with <italic>IGH</italic> on the derivative chromosome 14 and causing <italic>MYC</italic> over-expression [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. <italic>MYC</italic> also can be overexpressed by juxtaposition with <italic>IG</italic> light chain loci, via t(2;8)(p11;q24) and t(8;22)(q24;q11), on the derivative chromosome 8 as well as with a number of non-IG gene loci. <italic>MYC</italic> is now known to be a potent oncogene and dysregulation of <italic>MYC</italic>, as a result of gene rearrangement or other mechanism, has been shown to be associated with extremely aggressive clinical behavior in lymphoma patients [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. However, <italic>MYC</italic> over-expression alone cannot cause lymphoma [<xref rid="R3" ref-type="bibr">3</xref>] and t(8;14)(q24;q32) also has been found at very low levels in the blood and bone marrow of apparently healthy individuals, suggesting that <italic>MYC</italic> alterations alone are insufficient to trigger lymphomagenesis. Burkitt lymphoma and other lymphomas that carry <italic>MYC</italic> translocations are highly proliferative tumors. In contrast, in normal germinal centers, the lymphoid cell compartment with the highest proliferative fraction where many <italic>MYC</italic> rearranged lymphomas originate, Myc expression is tightly controlled and it is difficult to identify Myc expression [<xref rid="R1" ref-type="bibr">1</xref>]. These findings also implicate other mechanisms that are essential for lymphomagenesis in <italic>MYC</italic> dysregulated lymphomas.</p></sec><sec id="s2"><title>BIOLOGIC AND PHYSIOLOGIC FUNCTIONS OF MYC</title><p><italic>MYC</italic> is a basic helix-loop-helix transcription factor. Brodeur et al. found <italic>MYC</italic> in three forms, <italic>MYC</italic> (also known as C-<italic>MYC</italic>), <italic>MYCL</italic> and <italic>MYCN</italic> [<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R6" ref-type="bibr">6</xref>]. The <italic>MYC</italic>, <italic>MYC</italic>N (located at chromosome 2p24.3) and L-<italic>MYC</italic> (located at chromosome 1p34.2) genes encode transcription factors, i.e. proteins that bind to DNA and regulated transcription. <italic>MYC</italic> mRNA and Myc protein have very short half-life, approximately 10-25 minutes, respectively [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R10" ref-type="bibr">10</xref>]. Myc polypeptides have N-terminal and a C-terminal regions (Figure <xref ref-type="fig" rid="F1">1</xref>). The C-terminal domain contains a basic HLH-Zip (helix-loop-helix-leucine zipper) domain. This terminal is a noncoding and allows Myc to dimerize with the related partner protein, Max (<italic>MYC</italic>-associated protein X). Dimerization of Myc and Max forms complexes that bind to the E-box, a starting site for transcription. The coding exons of <italic>MYC</italic> encode for the N-terminal region which has a transcriptional regulatory domain, a region that contains conserved <italic>MYC</italic> Boxes I and II, followed by <italic>MYC</italic> Box III and IV, and a nuclear targeting sequence. The N-terminal region will bind with co-activator complexes, making Myc act as the transcription or repression factor [<xref rid="R1" ref-type="bibr">1</xref>]. In this review we focus on <italic>MYC</italic> (<italic>c-MYC</italic>) which has been identified as a global transcription factor. It regulates more than 10% of genes in the human genome and plays essential roles in promoting cell growth, increasing cellular metabolism and mitochondrial biogenesis, and biosynthesis of nucleic acids, ribosomes, and protein, and has an important role in apoptosis (Figure <xref ref-type="fig" rid="F2">2</xref>) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R11" ref-type="bibr">11</xref>].</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><bold>A.</bold>Functional domains of human c-<italic>MYC</italic> and its binding partner MAX; <bold>B.</bold> Structure of a Max homodimer bound to DNA.</p></caption><graphic xlink:href="oncotarget-06-38591-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Biology and regulation of Myc in cellular processes control</title><p>Myc is a key regulator of many biological activities including cell growth and division, cell-cycle progression, apoptosis, cell differentiation, cell metabolism, angiogenesis, cell adhesion and motility. Deregulation of Myc may result in apoptosis, genomic instability, uncontrolled cell proliferation, escape from immune surveillance, growth factor independence, and immortalization.</p></caption><graphic xlink:href="oncotarget-06-38591-g002"/></fig><p><italic>MYC</italic> is considered as an oncogene because of its diverse biologic activity. The oncogenic potential of <italic>MYC</italic> in lymphomagenesis was first shown in transgenic mice in 1985 [<xref rid="R12" ref-type="bibr">12</xref>]. It has been shown that juxtaposing <italic>MYC</italic> with the immunoglobulin &#x003bc; or &#x003ba; enhancer in transgenic mice leads to the development of immature and mature B-cell neoplasms. Furthermore, several mechanisms for <italic>MYC</italic> deregulation in malignancy have been identified, including chromosome translocation, gene amplification, and insertional viral mutagenesis [<xref rid="R2" ref-type="bibr">2</xref>].</p><p>Chromosome translocation of <italic>MYC</italic> resulting in deregulation occurs most often in lymphoma types associated with aggressive clinical behavior, and in large part <italic>MYC</italic> deregulation accounts for the aggressive behavior [<xref rid="R13" ref-type="bibr">13</xref>]. Virtually all lymphomas with <italic>MYC</italic> deregulation are of B-cell lineage and include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and BL (BCL-U), plasmablastic lymphoma, transformed follicular lymphoma, and rare <italic>de novo</italic> acute lymphoblastic lymphoma/leukemia (ALL).</p></sec><sec id="s3"><title>FUNCTIONAL REGULATION (TRANSCRIPTION, MICRO-RNAS AND APOPTOSIS)</title><sec id="s3_1"><title><italic>MYC</italic> as a transcription factor</title><p><italic>MYC</italic> acts as a transcription factor by binding with Max [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>], which depends on Enhancer Box (E-box) DNA sequence and recruitment of specific co-activator complexes [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. First, Myc-Max heterodimers start their activation of transcription by binding to the E-box [<xref rid="R14" ref-type="bibr">14</xref>]. After binding, transcriptional activation of <italic>MYC</italic> is mediated by binding to the histone acetyl-transferases, CBP/p300 and TIP60/GCN5, which requires the adaptor TRRAP, or the transcription factor P-TEFb/ubiquitin ligase SKP2, among others [<xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref>], resulting in transition from the G0/1 phase to the S phase. Myc also activates the expression of CCND2 (cyclin D2), cyclin-dependent kinases (CDKs) and down-regulates cell cycle inhibitors directly and indirectly. The cell phase transition ultimately induces cell proliferation and growth, DNA replication, protein biosynthesis, and regulation of metabolism and energy (Figure <xref ref-type="fig" rid="F2">2</xref>).</p></sec><sec id="s3_2"><title><italic>MYC</italic> - micro-RNAs regulations</title><p>Apart from inducing cell proliferation and growth, the <italic>MYC</italic> transcriptional network regulates a large number of micro-RNAs (miRs) that function as oncogenes or tumor suppressor genes. MiRNAs are small (18-22 nt) noncoding RNAs that negatively regulate gene expression through the inhibition of translation and destabilization of messenger RNAs (mRNAs) [<xref rid="R18" ref-type="bibr">18</xref>]. <italic>MYC</italic> only up-regulates the oncogenic miR17-92-cluster [<xref rid="R19" ref-type="bibr">19</xref>]. The miR17-92-polycistron is commonly amplified at 13q31 in several subtypes of aggressive lymphomas [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R20" ref-type="bibr">20</xref>]. Its oncogenic function is reflected by down-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten), TP53 and E2F1, causing the activation of the PI3K/AKT pathway and inhibiting cellular apoptosis. <italic>MYC</italic> represses several miRs with tumor suppressor function by the recruitment of HDACs. These miRs are miR15a/16-1, miR26a, miR29, and miR34 that regulate important functions in the neoplastic development such as apoptosis (miR-15a/16-1 and miR-34 targeting <italic>BCL2</italic> and <italic>TP53</italic>, respectively), proliferation (miR-29a targeting CDK6) or cell differentiation (miR-26a targeting EZH2) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R21" ref-type="bibr">21</xref>-<xref rid="R23" ref-type="bibr">23</xref>]. <italic>MYC</italic> is also negatively regulated by several miRs such as miR-34 and miR-494. MiR-494 is in turn repressed by EZH2 (enhancer of zeste homolog 2), making an auto-regulatory loop (<italic>MYC</italic>/miR-26a/EZH2/miR 494) that maintains persistent expression of <italic>MYC</italic> and EZH2 promoting the malignant phenotype (Figure <xref ref-type="fig" rid="F4">4</xref>) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R24" ref-type="bibr">24</xref>].</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><italic>MYC</italic>-mediated regulation and signaling pathways relevant to transcription, microRNA and apoptosis</title></caption><graphic xlink:href="oncotarget-06-38591-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title><italic>MYC</italic>-miRNA regulation in tumorgenesis</title><p>The aggresivity in clinical behavior are induced by <italic>MYC</italic> upregulation together with several miRNA downregulation. The upregulation of miR 17-92 and downregulation of miR15a/16-1, miR26a, miR 29, and miR 34 are also involved. Deregulation of these <italic>MYC</italic>s may result in uncontrolled cell proliferation, escape from immune surveillance and immortalization.</p></caption><graphic xlink:href="oncotarget-06-38591-g004"/></fig><p>Recent studies extend <italic>MYC</italic>'s broad activity to the entire non-coding transcriptome, including a larger and far less explored segment of the non-coding transcriptome, long non-coding RNAs (lncRNAs), which typically form functional secondary and higher order structures comprising protein-protein or protein-nucleic acid complexes [<xref rid="R25" ref-type="bibr">25</xref>]. LncRNAs are operationally defined as any non-protein-coding RNA &#x0003e; 200 nt in length, which corresponds to a convenient cut-off in biochemical fractionation and excludes all known classes of small RNAs [<xref rid="R26" ref-type="bibr">26</xref>]. Apart from encoding proteins, lncRNAs may have intrinsic functions as trans-acting regulatory RNAs, that in some contexts 3&#x02032;UTRs can be separately expressed and convey genetic functions in trans, and that both may be further processed to produce subsidiary species [<xref rid="R27" ref-type="bibr">27</xref>]. The genome-wide effects of <italic>MYC</italic> on the non-coding transcriptome were discovered by RNAseq analysis. However, for selected genes, these data have been independently validated for specific lncRNAs by determining steady-state RNA levels by qRT-PCR and direct transcriptional effects by nuclear run-on experiments. This data is augmented by visualization with global epigenetic and <italic>MYC</italic> ChIP data [<xref rid="R25" ref-type="bibr">25</xref>].</p><p><italic>MYC</italic> can also undergo transcriptional repression through several mechanisms. One mechanism is the interaction of these complexes with the transcription factor Miz-1 [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. This interaction prevents recruitment of the activating molecule p300 and facilitates the binding of the gene silencing DNA-methyltransferase, DNMT3a. Another mechanism of transcriptional repression occurs by transcription factors, such as Mad, titrating out Myc from the complexes allowing Max/Mad heterodimers to recruit histone deacetylases (HDAC) that cause repression of gene transcription. <italic>MYC</italic> may also repress gene expression by recruitment of HDAC to promoters containing E-boxes [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R28" ref-type="bibr">28</xref>].</p><p>The gene profile transcriptionally regulated by <italic>MYC</italic> varies in different cell types with relatively little overlap [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. Two recent studies showed that Myc, instead of activating a particular gene signature, can act as an amplifier of transcribed genes in a given cell by uploading to the promoters of active genes and enhancing their transcription. This function of <italic>MYC</italic> may be relevant to the increased aggressiveness of tumors associated with other oncogenic events carrying <italic>MYC</italic> alterations, and may offer for an opportunity to develop novel targeted therapies in the future [<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>].</p></sec><sec id="s3_3"><title><italic>MYC</italic> and apoptosis</title><p>In 2008, Hoffman &#x00026; Liebermann demonstrated that elevated expression of <italic>MYC</italic> can induces apoptosis. Similar observations also were made for other oncogenic transcription factors such as E1A and E2F1 (Figure <xref ref-type="fig" rid="F3">3</xref>) [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R32" ref-type="bibr">32</xref>]. The biological meaning of this function is not fully understood, but has been interpreted as a cellular protective mechanism to counteract the effects of oncogenic activation and to avoid propagation of transformed cells.</p><p>The mechanisms of <italic>MYC</italic>-mediated apoptosis may involve several pathways. Overexpression of <italic>MYC</italic> increases DNA replication and possibly results in DNA damage that, in turn, triggers a <italic>TP53</italic>-mediated response leading to apoptosis [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R33" ref-type="bibr">33</xref>]. Myc expression also seems to downregulate, probably indirectly, anti-apoptotic proteins such as Bcl2 or Bcl-XL and upregulate pro-apoptotic elements such as BIM. This anti-tumorigenic effect of <italic>MYC</italic> may explain the need of other cooperative mechanisms for cell transformation and tumor progression.</p><p>There are some synthetic lethal interactions between Myc and some other molecular pathways. Identification of these <italic>MYC</italic> &#x0201c;synthetic lethal&#x0201d; pathways might facilitate therapeutic targeting of <italic>MYC-</italic>driven cancers. Recent studies indicate that BL cells are selected for B-cell receptor (BCR) expression. Given the essential role of the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) pathway in tonic BCR signaling, recent studies have addressed the potential cooperation of <italic>MYC</italic> and the BCR-dependent PI3K pathway [<xref rid="R34" ref-type="bibr">34</xref>]. Activation of PI3K pathway is also observed in human BL, especially in the sporadic subtype. Increased activity of the PI3K pathway in these tumors is a result of either gain of function mutations of TCF3 (transcription factor 3), or loss of function mutations of its negative regulator ID3 (inhibitor of DNA binding 3), that augment the BCR signaling [<xref rid="R35" ref-type="bibr">35</xref>]. The PIM family of oncogenic kinases is another group of proteins potentiating and consolidating <italic>MYC</italic>-dependent lymphomagenesis. PIMs directly phosphorylate and stabilize the Myc protein, but also prevent <italic>MYC-</italic>induced apoptosis by phosphorylation and inactivation of the proapoptotic protein BAD (<italic>BCL2-</italic>associated agonist of cell death) [<xref rid="R36" ref-type="bibr">36</xref>]. In addition, overexpression of <italic>MYC</italic> and Pims in mouse pre-B cells resulted in rapid proliferation but also an inhibition of differentiation, whereas genetic or pharmaceutical inhibition of Pim kinases decreased the proliferation of cells overexpressing Myc [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>].</p><p>The relevant oncogenic role of <italic>MYC</italic> has stimulated the search for therapeutic strategies that may counteract its damaging functions. Myc protein itself has been generally considered &#x0201c;undruggable&#x0201d; and therefore potential therapeutic approaches have been directed to reduce its expression, interfere with Max dimerization or DNA binding or acting on downstream target genes. However, most of these strategies have been difficult to apply <italic>in vivo</italic> in models [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R38" ref-type="bibr">38</xref>]. The recent discovery that <italic>MYC</italic> transcription depends on the regulatory function of BRD4 offers new potential therapeutic opportunities [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R40" ref-type="bibr">40</xref>]. BRD4 is a member of the bromodomain and extraterminal (BET) subfamily of proteins that can bind to lysine acetylated histones and recruit elements required for transcription [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. Two small molecules, JQ1 and iBET, displace BRD4 from acetylated chromatin resulting in downregulation of <italic>MYC</italic> and modulation of its transcriptional program, including the upregulation of <italic>MYC</italic> repressed miRNAs, with a marked anti-proliferative cell effect and tumor growth inhibition [<xref rid="R1" ref-type="bibr">1</xref>]. These results have been confirmed in plasma cell myeloma (PCM) and BL cell lines with translocated <italic>IGH/MYC</italic> and also in aggressive lymphomas with <italic>MYC</italic> overexpression not related to structural gene alterations, suggesting that this strategy may be useful in a broad spectrum of <italic>MYC</italic> driven tumors. Although BRD4 binds to a high number of enhancers and promoters, its inhibition is particularly sensitive in very large and active enhancers called super-enhancers that regulate oncogenes such as <italic>MYC</italic>. The addiction of PCM cells to <italic>MYC</italic> makes the cells particularly sensitive to the BRD4 binding disruption on its super enhancer [<xref rid="R41" ref-type="bibr">41</xref>].</p></sec></sec><sec id="s4"><title>MYC REGULATION IN GERMINAL CENTER B-CELLS</title><p><italic>MYC</italic> is initially expressed in B cells after interaction with antigens and T cells and is essential for germinal center (GC) formation [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R42" ref-type="bibr">42</xref>]. Myc activates the cyclin-dependent kinase (CDK) complex, including cyclin D2 (CCND2). Through activation of this protein, Myc cause activation of cycle cell from the resting cell to become active cell.</p><p>After starting GC formation, Myc expression in GC is gradually suppressed by Bcl6 (B-cell lymphoma 6 protein). Bcl6, by binding with MIZ1 (ZBTB17), a known partner of <italic>MYC</italic>, represses transcription of <italic>MYC</italic> and inhibits CCND2 expression [<xref rid="R1" ref-type="bibr">1</xref>]. Switching gene expression from <italic>MYC</italic> to <italic>BCL6</italic> causes formation of the dark zone of GC. When Myc expression in dark zone GC is absent, TCF3 (E2A) acts as a transcription factor. TCF3 together with CCND3 acts in the dark zone of the GC to make these cells highly proliferative [<xref rid="R43" ref-type="bibr">43</xref>].</p><p>In the GC microenvironment, rapidly dividing B cells undergo somatic hypermutation and class-switch recombination of their immunoglobulin genes; both of these processes involve DNA strand breaks. These processes increase the probabil&#x000ad;ity of oncogenic events such as chromosomal rearrangements. In human GC-derived B cell lymphomas, the <italic>MYC</italic> gene is frequently involved in chromosomal translocations. Of note, it has been reported that cytidine deaminase (AID) is essential for the <italic>MYC</italic>/<italic>IgH</italic> chromosome translocations induced by IL6. AID is expressed in germinal center B cells, and most human B cell cancers represent germinal center or post- germinal center cells. <italic>MYC/IgH</italic> translocations in IL6 transgenic mice that are mutant for activation induced AID that initiates aberrant Ig class switch recombination [<xref rid="R44" ref-type="bibr">44</xref>].</p><p>TCF3 (E2A) not only acts as a transcription factor, but also induces its own negative inhibitor, ID3 [<xref rid="R45" ref-type="bibr">45</xref>]. ID3 inhibiting TCF3 causes the B-cell moving from the dark to the light zone. In this light zone, B-cells express IRF4 whereas Bcl6 is downregulated. Myc is re-expressed once the cells have been upregulated through NF-kB. This upregulation is again dependent on antigen and T-cell interactions.</p><p>The light zone <italic>Myc</italic>-positive cells have high-affinity BCRs and they can re-enter the dark zone, proliferate, and further acquire IG somatic mutations perpetuating the GC reaction. This is a highly interactive process. <italic>Myc</italic>-negative cells in the light zone exit the GC to become memory cells or early plasmablasts. Induction of BLIMP1 in plasmablasts causes plasma cell differentiation and represses Myc expression by binding to its promoter.</p></sec><sec id="s5"><title>GENOMIC AND EPIGENETIC ABERRATIONS</title><p>Gene amplification, translocations, point mutations, epigenetic reprogramming, enhanced translation and increased protein stability resulting in over-expression can induce <italic>MYC</italic> oncogenetic deregulation. <italic>MYC</italic> deregulation can be found in 80% of breast cancers, 70% of colon cancers, 90% of gynecological cancers, 50% of hepatocellular carcinomas, 30% of lung cancers and in many of hematological tumors.</p><p>Generally, <italic>MYC</italic> amplification has been described as the most frequent molecular alteration in most of solid tumors. Addition of single-nucleotide polymorphisms (SNPs) to the 8q24 chromosomal region has been associated with colorectal, bladder, breast, ovarian and prostate cancers.</p><p>The t(8;14)/<italic>MYC-IGH</italic> is the most frequent aberration involving the <italic>MYC</italic> gene in Burkitt lymphoma. Less common translocations involve the IG light chains, t(2;8)/<italic>KAPPA-MYC</italic> and t(8;22)/<italic>MYC-LAMBDA</italic> [<xref rid="R1" ref-type="bibr">1</xref>]. Activation of <italic>MYC</italic> gene is considered the main pathogenetic feature of Burkitt lymphoma, but other genetic mutations are also essential for lymphomagenesis. <italic>MYC</italic> rearrangement has been observed in 5-10% of diffuse large B-cell lymphomas and up to 50% of high-grade B-cell lymphomas other than Burkitt lymphoma. In these tumors, <italic>MYC</italic> translocations can also involve non-IG partners. Our recent study showed that <italic>MYC</italic> rearrangements are detected in 9% of diffuse large B-cell lymphomas. Patients with <italic>MYC</italic> rearranged diffuse large B-cell lymphomas more frequently present with bulky disease, fail to achieve complete remission with R-CHOP therapy and have poorer disease-specific survival, independent of the International Prognostic Index, if their tumors express Myc protein in more than half of the tumor cells [<xref rid="R46" ref-type="bibr">46</xref>]. Lu et al study showed that patients with <italic>MYC</italic> or <italic>BCL2</italic> copy number aberration (CNA) had significantly worse overall survival (OS) and progression-free survival (PFS) than negative cases (<italic>P</italic>&#x0003c;0.0001). Patients with both <italic>MYC</italic> and <italic>BCL2</italic> copy number aberration had similar outcomes to those with classic double-hit lymphoma (DHL) or protein double expression lymphoma (<italic>MYC</italic> and <italic>BCL2</italic>/<italic>BCL6</italic> coexpression) [<xref rid="R47" ref-type="bibr">47</xref>].</p><p>Myc protein overexpression as a result of point mutations in <italic>MYC</italic> N-terminal domain (residues 44-65) is also common. The most frequently mutated residue was Thr-58. Normally, the phosphorylation of Thr-58 can control Myc degradation and mutations. Mutation at Thr-58 causes an increase of Myc half-life in Burkitt lymphoma.</p><p>The mechanism by which Myc represses gene expression is less well understood. Schneider et al. reported that Myc acts to repress gene expression by binding with Miz-1. Wanzel et al. and Seoane et al. describe the role of Myc-Miz-1 interaction through TGF&#x003b2; signaling pathway. In the absence of TGF&#x003b2;, Myc represses CDKN2B by binding to Miz-1 and displacing Miz-1 cofactors. In the presence of TGF&#x003b2;, Myc expression is suppressed. Then the Smad transcription factor translocates and binds with Miz-1, causing recruitment of Miz-1 cofactor, NPM1. The NPM1 recruitment causes stimulation of CDKN2B transcription, then induces cell cycle arrest. Myc also activates many ribosomal protein genes, one of which is Rpl23. This gene can bind to NPM1 in the nucleolus, and then cause inhibition of Miz-1 activity. Based on this description, NPM1 was described as a positive Myc coactivator [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R49" ref-type="bibr">49</xref>].</p><p>Another critical mechanism for Myc-mediated gene repression is through its ability to activate microRNAs, resulting in E2F1 activity suppression, and TGF&#x003b2; signaling pathway suppression [<xref rid="R50" ref-type="bibr">50</xref>]. Myc also represses many more microRNAs, resulting in increased gene expression at the protein level.</p></sec><sec id="s6"><title>DETECTION OF MYC DEREGULATION</title><p>Detection of <italic>MYC</italic> rearrangement has become an aid in the diagnosis of BL and PBL and a prognostic marker in other aggressive B-cell lymphomas. There are several techniques to detect <italic>MYC</italic> deregulation: conventional cytogenetics, fluorescence <italic>in situ</italic> hybridization (FISH), and immunohistochemistry (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Comparison of different detection techniques of <italic>MYC</italic>deregulation</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Techniques</th><th align="left" valign="middle" rowspan="1" colspan="1">Method</th><th align="left" valign="middle" rowspan="1" colspan="1">Advantages</th><th align="left" valign="middle" rowspan="1" colspan="1">Disadvantages</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Conventional cytogenetics [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Assessing <italic>MYC</italic> translocations by determining the partner chromosome and gene, and can also determine whether the tumor has a simple or complex karyotype.</td><td align="left" valign="middle" rowspan="1" colspan="1">It is helpful to distinguishing some cases of BL from BCL-U.<break/>It is a very good and well-established method to survey the entire tumor genome.</td><td align="left" valign="middle" rowspan="1" colspan="1">It requires fresh viable tissue.<break/>A time-consuming and labor-intensive technique with a relatively long turnaround time (days to weeks).<break/>Requires skilled cytogenetic technologists and cytogeneticists to perform and interpret.<break/>It is only can be done at reference laboratories.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FISH [<xref rid="R53" ref-type="bibr">53</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Using fluorochrome-conjugated DNA complimentary to the <italic>MYC</italic> gene, to identify <italic>MYC</italic> gene rearrangement.</td><td align="left" valign="middle" rowspan="1" colspan="1">Can be performed on both fresh and formalin-fixed paraffin-embedded tissue.<break/>Shorter turn-around time (days).</td><td align="left" valign="middle" rowspan="1" colspan="1">Cannot identify the <italic>MYC</italic> translocation partner.<break/>Sometimes it can get false negatives result because the distribution of the breakpoints genomic region is large, approximately1000 kb.<break/>Require specialized personal to perform.<break/>It is only can be done at reference laboratories.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Immunohistochemistry [<xref rid="R54" ref-type="bibr">54</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Using rabbit monoclonal antibody (Epitomics, clone Y69) that targets the N-terminus of <italic>MYC</italic> to assess the differential expression of <italic>MYC</italic> in various aggressive B-cell lymphomas.</td><td align="left" valign="middle" rowspan="1" colspan="1">It can be performed quickly.<break/>It can be performed in most anatomic pathology laboratories.<break/>It can be assessed by a pathologist.</td><td align="left" valign="middle" rowspan="1" colspan="1">This method need more study to make the result become more valid.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CGH Array [<xref rid="R55" ref-type="bibr">55</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Comparing DNA extracted from the tumor to a commercially available pooled normal DNA control by using a high density 4&#x000d7;44K oligonucleotide array.</td><td align="left" valign="middle" rowspan="1" colspan="1">Can quantitatively detect single copy gains and losses and high level amplications in an experiment.<break/>Can detect these aberrations on a single clone.</td><td align="left" valign="middle" rowspan="1" colspan="1">It is unable to detect aberrations that do not result in copy number changes.<break/>It is limited in its ability to detect mosaicism.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gene expression profile [<xref rid="R56" ref-type="bibr">56</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Transcriptome sequencing was carried out by RNA sequencing, and genes identified were validated using real-time PCR, which is used to amplify and simultaneously detect or quantify a targeted <italic>MYC</italic> DNA molecule.</td><td align="left" valign="middle" rowspan="1" colspan="1">RT-PCR allows quantification of the desired product at any point in the amplification process by measuring fluorescence.</td><td align="left" valign="middle" rowspan="1" colspan="1">Financial constraints limit expression profiling experiments to a small number of observations of the same gene under identical conditions, reducing the statistical power of the experiment.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Whole exome sequencing [<xref rid="R57" ref-type="bibr">57</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Sequencing all the protein-coding genes in a genome: Genomic DNA samples from patients were fragmented, ligated to Illumina multiplexing paired-end adapters, amplified by means of a PCR assay, and hybridized to biotin-labeled VCRome, a solution-based exome capture reagent that was designed in-house and is commercially available.</td><td align="left" valign="middle" rowspan="1" colspan="1">It is the most efficient way to identify the genetic variants in all of an individual's genes.</td><td align="left" valign="middle" rowspan="1" colspan="1">It is only able to identify those variants found in the coding region of genes which affect protein function.<break/>It's expensive relative to other technologies.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RPPA proteinic Array [<xref rid="R58" ref-type="bibr">58</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">Sample cells are isolated from Myc patients and are lysed. The lysate is arrayed onto the microarray and probed with fluorescent antibodies against the target protein. Reference peptides are printed on the slides to allow for protein quantification of the sample lysates.</td><td align="left" valign="middle" rowspan="1" colspan="1">It is rapid, automated and highly sensitive, consuming small quantities of samples and reagents.</td><td align="left" valign="middle" rowspan="1" colspan="1">Proteins are more difficult to handle. A protein chip requires a lot more steps in its creation.<break/>It usually requires fresh reference peptides.</td></tr></tbody></table></table-wrap><p>Karyotyping is a useful tool to assess for <italic>MYC</italic> translocations. This method can determine the partner chromosome involved in the translocation and also can determine whether the tumor has a simple or complex karyotype. A complex karyotype is gross evidence of other genetic abnormalities likely involved in lymphomagenesis or progression. This technique is helpful for distinguishing BL from BCL-U. However, when in daily practice, this technique has disadvantages. Conventional cytogenetics requires fresh, viable tissue and the results can take several days to up to 2-3 weeks to be available. This method also requires skilled cytogenetic technologists and cytogeneticists and is therefore usually performed in reference laboratories.</p><p>Fluorescence <italic>in situ</italic> hybridization (FISH) analysis is another useful technique to detect abnormalities of <italic>MYC</italic>. By using fluorochrome-conjugated DNA probes complementary to <italic>MYC</italic>, FISH can identify gene rearrangement using break-apart or dual fusion strategies. This technique can be performed on fresh viable tissue or formalin-fixed paraffin-embedded tissue sections and the turnaround time is shorter than conventional cytogenetics. However, FISH also has disadvantages. If a <italic>MYC</italic> break-apart probe is used, theoretically all gene rearrangements will be detected but this approach cannot provide information about the translocation partner. A second approach is a dual fusion strategy using probes specific for <italic>IGH</italic> and <italic>MYC</italic>. This approach detects t(8:14)/<italic>MYC-IGH,</italic> but cannot detect <italic>IG light chain (IGL)</italic> partners or non-IG <italic>MYC</italic> partners. (<italic>Light chain</italic> probes are not routinely available in most clinical laboratories.) In addition, dual fusion FISH sometimes can yield a false negative result if the distribution of the breakpoints is large around 1000 kb [<xref rid="R53" ref-type="bibr">53</xref>].</p><p>Another strategy for detecting <italic>MYC</italic> deregulation is immunohistochemistry using a novel rabbit monoclonal antibody (Epitomics, clone Y69) [<xref rid="R54" ref-type="bibr">54</xref>]. This reagent targets the N-terminus of <italic>MYC</italic> and can be used on paraffin-embedded tissue sections. Immunohistochemical assessment of Myc is advantageous in that it can be performed quickly and readily assessed in most anatomic pathology laboratories. Several recent studies have used this antibody to assess the differential expression of Myc in various aggressive B-cell lymphomas. Others have reported that nuclear or mixed nuclear and cytoplasmic staining for Myc correlates with <italic>MYC</italic> rearrangement. Ruzinova et al found that a primarily nuclear or mixed nuclear and cytoplasmic staining pattern for Myc in an aggressive B-cell lymphoma is highly predictive of a <italic>MYC</italic> translocation (positive-predictive value = 0.92, negative-predictive value = 0.95, <italic>P</italic> &#x0003c; 0.0001) and showed that the subcellular localization of Myc can be determined with good interobserver agreement among pathologists (k statistic = 0.90) [<xref rid="R59" ref-type="bibr">59</xref>]. Green et al analyzed the correlation between <italic>MYC</italic> rearrangement and Myc protein expression in 219 aggressive lymphomas in FISH and IHC study. In the study, 93% of cases with an <italic>MYC</italic> break had &#x02265;80% Myc<sup>+</sup> cells, in contrast to 3% of non-rearranged cases (<italic>P</italic> &#x0003c; 0.0001). Receiver operating characteristic curve analysis showed &#x02265;70% Myc<sup>+</sup> tumor cells to be the optimal cutoff sensitivity=100%, specificity=93%). Area under the receiver operating characteristic curve was 0.992, indicating that immunostaining for Myc protein is an excellent screening test to predict whether an <italic>MYC</italic> rearrangement is present [<xref rid="R60" ref-type="bibr">60</xref>]. Similarly, an international collaboration reported that only 11% of 167 patients with DLBCL had <italic>MYC</italic> translocations when using FISH, whereas IHC indicated that 29% of patients were positive for Myc protein expression [<xref rid="R61" ref-type="bibr">61</xref>]. Green et al show the value of simple immunohistochemical evaluation of <italic>Myc</italic> and <italic>BCL2</italic> expression for identifying patients with DLBCL with double-hit biology. Using this immunohistochemical approach, 29% of patients with DLBCL had DHL biology, which was strongly associated with poor prognosis after standard R-CHOP therapy [<xref rid="R62" ref-type="bibr">62</xref>-<xref rid="R64" ref-type="bibr">64</xref>]. However, immunohistochemistry is still not equivalent to the detection of <italic>MYC</italic> translocations [<xref rid="R59" ref-type="bibr">59</xref>, <xref rid="R61" ref-type="bibr">61</xref>-<xref rid="R64" ref-type="bibr">64</xref>].</p></sec><sec id="s7"><title>MYC DYSREGULATION IN AGGRESSIVE LYMPHOMA, DIAGNOSIS AND CLASSIFICATION</title><p><italic>MYC</italic> gene alterations were identified initially in lymphoid neoplasms by cytogenetic and molecular genetic studies that recognized 8q24 translocations and <italic>MYC</italic> gene rearrangements, amplifications, or mutations. These aggressive lymphomas also have additional oncogenic alterations that cooperate with <italic>MYC</italic> dysregulation by counteracting especially its proapoptotic function.</p><sec id="s7_1"><title>Burkitt lymphoma (BL)</title><p>Burkitt lymphoma (BL) was first described by Denis Burkitt as a sarcoma involving the jaws of African children. Burkitt lymphoma is a mature B-cell lymphoma composed of very highly proliferating cells. Burkitt lymphoma has a germinal center B-cell (GCB) immunophenotype and is positive for the pan-B-cell antigens CD20, CD79a, and PAX5, and germinal center antigens CD10 and Bcl6.</p><p>In the World Health Organization (WHO) classification, BL is subdivided into three variants: endemic BL (eBL), sporadic BL (sBL) and immunodeficiency-associated BL (iBL). The endemic variant can be found in young children at equatorial Africa, South America, and New Guinea. This variant is highly associated with Epstein-Barr virus (EBV) infection and usually occurs at extranodal sites, often involving facial bones and the abdomen. The sporadic variant is seen mostly in resource-rich nations throughout the world in adolescents and young adults. Sporadic BL is occasionally associated with EBV infection, about 20% of cases, and usually occurs within the abdomen, most frequently affecting the ileocecal region of the gastrointestinal tract. The immunodeficiency-associated variant is seen principally in patients infected with human immunodeficiency virus (HIV). About 30-40% of cases are associated with EBV infection. This variant can involve lymph nodes and extranodal sites; bone marrow involvement is more common in this variant [<xref rid="R65" ref-type="bibr">65</xref>]. The genetic hallmark of BL is <italic>MYC</italic> translocation (Figure <xref ref-type="fig" rid="F5">5</xref>) usually with the <italic>IGH</italic> locus but also with <italic>IGL</italic> loci (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title><italic>MYC</italic> translocations in aggressive B-cell lymphomas</title><p><bold>A.</bold>-<bold>H.</bold> Burkitt lymphoma. The lymphoma cells are monotonous in cell size with frequent apoptotic bodies and mitotic figures. Tingle-body macrophages are often seen with Starry-Sky pattern <bold>A.</bold> The tumor cells are positive for CD10 <bold>B.</bold>, BCL6 <bold>D.</bold>, FOXP-1 <bold>F.</bold>, high proliferation by Ki-67 <bold>G.</bold>, negative for BCL2 <bold>C.</bold> and MUM-1 <bold>E.</bold> All images, x 60 magnification. FISH showed t(8;14) as a sole cytogenetic abnormality <bold>H.</bold> x 100 magnification. <bold>I.</bold>-<bold>P.</bold> Diffuse large B-Cell Lymphoma, activated B-cell immunophenotype. The lymphoma cells are heterogeneous in cell size with occasional apoptotic bodies and mitotic figures. Reactive histiocytes and vascular proliferation are seen <bold>I.</bold> The tumor cells are positive for BCL2 <bold>K.</bold>, BCL6 <bold>L.</bold>, MUM-1 <bold>M.</bold>, FOXP-1 <bold>N.</bold>, high proliferation by Ki-67 <bold>O.</bold>, negative for CD10 <bold>J.</bold> All images, x 60 magnification. FISH showed non-IgH MYC gene translocation and disruption of MYC gene using break-part MYC probe <bold>P.</bold>, x 100 magnification. <bold>Q.</bold>-<bold>X.</bold> B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL, <bold>D.</bold> Plasmablastic lymphoma. The lymphoma cells are relatively monotonous in cell size with frequent mitosis. Tingle-body macrophages are present but uncommon <bold>Q.</bold> The tumor cells are positive for CD10 <bold>R.</bold>, BCL2 <bold>S.</bold>, BCL6 <bold>T.</bold>, FOXP-1 <bold>V.</bold>, high proliferation by Ki-67 <bold>W.</bold>, negative for MUM-1 <bold>U.</bold>. All images, x 60 magnification. FISH showed a complex cytogenetic abnormality with t(8;14) and MYC gene amplification <bold>X.</bold>, x 100 magnification. (Y-F1) Plasmablastic lymphoma. The lymphoma cells are polymorphous in cell size with abundant cytoplasm. Reactive histiocytes and vascular proliferation are seen (Y). The tumor cells are positive for BCL6 (B1), MUM-1 (C1), FOXP-1 (D1), high proliferation by Ki-67 (E1), CD38 (F1), negative for CD10 (Z) and BCL2 (A1). FISH identified a complex cytogenetic abnormality with t(8;14). All images, x 60 magnification.</p></caption><graphic xlink:href="oncotarget-06-38591-g005a"/><graphic xlink:href="oncotarget-06-38591-g005b"/></fig><p>Beside from <italic>MYC</italic> translocations, <italic>MYC</italic> and <italic>TP53</italic> mutations also can be found in BL, in about 60% and 40% of the cases, respectively. Most of these mutations target functional domains that enhance the oncogenic potential of <italic>MYC</italic> by different mechanisms, including increased protein stability and transcriptional function or by impairing the induction of the proapoptotic element <italic>BIM</italic> [<xref rid="R72" ref-type="bibr">72</xref>].</p><p>The gene expression profile of BL is similar to the cells in GC dark zone. This relationship seems contradictary since Myc is usually not expressed in the GC dark zone. <italic>TCF3</italic> and <italic>ID3</italic> mutations can be found in BL. The <italic>ID3</italic> mutations (38-68%) are more frequent than those of <italic>TCF3</italic> (11%), which have been found in about 70% of sporadic type and HIV-associated type BL but only 40% in endemic type BL. These mutations are important for the survival of BL cells, as <italic>ID3</italic> mutation causes constitutive TCF3 activation. Constitutive TCF3 activation strengthens BCR signaling through phosphoinositide-3-kinase (PI3K) pathway and CCND3 upregulation, causing cell survival and proliferation, respectively [<xref rid="R43" ref-type="bibr">43</xref>]. <italic>CCND3</italic> mutations can also be found in 38% of sporadic BL and occasional endemic tumors. Abnormalities in these three genes are important pathologic mechanisms involved in BL development (Figure <xref ref-type="fig" rid="F6">6</xref>).</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Somatic mutations in Burkitt lymphoma frequently target ID3, TCF3 and CCND3</title><p><bold>A.</bold> TCF3 modulates germinal center genes and is preferentially expressed in the highly proliferative area of this structure, recognized histologically as the dark zone (DZ). TCF3 also regulates survival and proliferation of lymphoid cells through the BCR and PI3K signaling pathway and by modulating cell cycle regulators such as CCND3. TCF3 also induces its own inhibitor ID3, creating an autoregulatory loop that may attenuate this program and facilitate the transition of the germinal center cells to the light zone (LZ). <italic>MYC</italic> is not normally expressed in cells of the DZ and is upregulated in the LZ. Its induction of ID3 may contribute to the attenuation of the TCF3 pathway in the normal germinal center B-cells. Ki-67 shows active proliferation of DZ B-cells. <bold>B.</bold> Burkitt lymphoma (top) frequently harbors mutations in ID3, TCF3 and CCND3 that activate the TCF3 pathway. The t(8:14) translocation present in BL dysregulates <italic>MYC</italic>. Cooperation of these two pathways plays a crucial role in BL, in which virtually all cells are proliferating, as evidenced by the expression of the cell cycle&#x02013;related antigen Ki-67 (bottom).</p></caption><graphic xlink:href="oncotarget-06-38591-g006"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Aggressive B-cell lymphomas associated with recurrent MYC rearrangement</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Lymphoma</th><th align="left" valign="middle" rowspan="1" colspan="1">Morphology</th><th align="left" valign="middle" rowspan="1" colspan="1">Karyotype</th><th align="left" valign="middle" rowspan="1" colspan="1"><italic>MYC</italic> Rearrangement</th><th align="left" valign="middle" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">BL</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohesive architecture Diffuse &#x0201c;starry-sky&#x0201d; proliferation of monomorphic medium-sized lymphocytes</td><td align="left" valign="middle" rowspan="1" colspan="1">Simple</td><td align="left" valign="middle" rowspan="1" colspan="1">Present in &#x0003e;90% of cases Translocations involve IG partner genes only 85% t(8;14):IG&#x003ba;, IG&#x003bb; 15% t(2;8),t(8;22) Not associated with <italic>BCL2/BCL6</italic> translocation</td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="R66" ref-type="bibr">66</xref>-<xref rid="R68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">BCL-U</td><td align="left" valign="middle" rowspan="1" colspan="1">Often cohesive architecture &#x0201c;Intermediate&#x0201d; features of both DLBCL and BL</td><td align="left" valign="middle" rowspan="1" colspan="1">Complex</td><td align="left" valign="middle" rowspan="2" colspan="1">Present in 35%-50% of cases<break/>Translocations involve IG or non-IG partner genes, rarely involve IGH.<break/>Frequently associated with <italic>BCL2/BCL6</italic> translocation</td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="R67" ref-type="bibr">67</xref>, <xref rid="R68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Variable architecture<break/>Diffuse proliferation of pleomorphic medium-to-large sized centroblastic, immunoblastic, or anaplastic lymphocytes</td><td align="left" valign="middle" rowspan="1" colspan="1">Complex</td><td align="left" valign="middle" rowspan="1" colspan="1">Present in 5%-14% of de novo cases<break/>Translocations involve IG or non-IG partner genes 50%-70% associated with <italic>BCL2/BCL6</italic> translocation</td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R69" ref-type="bibr">69</xref>, <xref rid="R70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBL</td><td align="left" valign="middle" rowspan="1" colspan="1">Diffuse proliferation of large immunoblastic and/or plasmacytic lymphocytes</td><td align="left" valign="middle" rowspan="1" colspan="1">Complex</td><td align="left" valign="middle" rowspan="1" colspan="1">Present in 50% of cases Translocations involve IG partner genes in most cases, usually IGH Not associated with<italic>BCL2/BCL6</italic> translocation</td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="R71" ref-type="bibr">71</xref>]</td></tr></tbody></table><table-wrap-foot><p>Note: BCL-U indicates B-cell lymphoma, unclassifiable with features intermediate between DLBCL and BL; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; PBL, plasmablastic lymphoma.</p></table-wrap-foot></table-wrap><p>However, molecular studies show that a small group of B cell lymphoma reminiscent of BL without <italic>MYC</italic> translocation carries the same GEP signature than BL. These cases are <italic>MYC</italic>-negative, high-grade B-cell lymphomas sharing a recurrent pattern of 11q aberration and similarities with but not being BL. Moreover, lymphomas with the typical 11q-gain/loss pattern seem to have more frequently nodal presentation than BL from patients younger than 40 years (82% vs 55%, <italic>P</italic>=0.074). The specific characteristics detected in this group of lymphomas raise the question of whether these lymphomas truly belong to the entity of BL and the presence of the typical 11q-gain/loss pattern could be a genetic hallmark that defines this group of cases [<xref rid="R73" ref-type="bibr">73</xref>].</p><p>Moreover, to define BL more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas, some studies used gene expression profiling to define a molecular BL (mBL) phenotype that would aid accurate diagnosis [<xref rid="R74" ref-type="bibr">74</xref>, <xref rid="R75" ref-type="bibr">75</xref>]. Hummel et al devised a computational algorithm called &#x0201c;core-group extension.&#x0201d; Given a predefined core group of expression profiles that satisfied the WHO criteria for Burkitt's lymphoma (a consensus histologic classification of classic or atypical BL, CD20<sup>+</sup>, BCL6<sup>+</sup>, CD10<sup>+</sup>, BCL2<sup>&#x02212;</sup>, CD5<sup>&#x02212;</sup>, IG-myc<sup>+</sup>, and Ki-67 score &#x02265;95%), the algorithm identified additional cases that have a similar pattern of gene expression and identified 58 genes that constituted the molecular Burkitt's lymphoma (mBL) signature. Each case was assigned an mBL-signature index score between 0 and 1, with a higher score reflecting a greater similarity of gene expression in the sample to that in the core group. Cases with an index score greater than 0.95 were classified as mBL. The distinctive mBL signature consisted of 58 genes, including several target genes of the NF-&#x003ba;B pathway (i.e., <italic>BCL2A1, FLIP</italic>, <italic>CD44</italic>, <italic>NFKBIA</italic>, <italic>BCL3,</italic> and <italic>STAT3</italic>) that are known to distinguish activated B-cell-like or germinal center B-cell-like lymphomas.</p><p>Using 95% similarity to a consensus mBL gene signature as the criterion, all classical BLs and almost all atypical BLs displayed an mBL phenotype, as did some (but not all) rare DLBCLs with ambiguous features [<xref rid="R74" ref-type="bibr">74</xref>]. A mBL represents a well-defined entity with very distinctive clinical and biological features which is well characterized by gene expression analysis, even if morphological features are inconsistent with BL.</p></sec><sec id="s7_2"><title>Diffuse large B-cell lymphoma</title><p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in the world, accounting for 30% to 40% of all lymphoma cases. This disease usually occurs in adults and patients can present with nodal or extranodal sites of disease. Tumors consist of a diffuse proliferation of medium-large atypical lymphocytes that may resemble centroblasts, immunoblasts, or anaplastic cells. The neoplastic cells express pan B-cell antigens such as CD19, CD20, CD79a and PAX5 and variably express the anti-apoptosis protein Bcl2. Using immunohistochemistry and antibodies specific for CD10, Bcl6, MUM1, GCET1, and FOXP1 as a surrogate for gene expression profiling, DLBCL was divided into 2 subtypes, germinal center (GC), non-GCB; a subset of cases are unclassified [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R65" ref-type="bibr">65</xref>]. Dybkaer et al propose a refined classification system based on subset-specific B-cell-associated gene signatures (BAGS) in the normal B-cell hierarchy, hypothesizing that classification of the phenotypic cell of origin after gene signature assignment in malignant B-cell disorders should be assessed for clinical impact by end points, including diagnosis, prognosis, and prediction of therapeutic outcome [<xref rid="R76" ref-type="bibr">76</xref>].</p><p>Based on clinical and biological factors, several studies have examined the prognostic factors that may predict response to therapy. These factors include: the International Prognostic Index (IPI), concordant bone marrow involvement, Bcl2 expression, <italic>BCL6</italic> gene rearrangement and Bcl6 expression. Several studies have shown that patients with DLBCL with a GCB expression profile have a better prognosis and response to therapy than patients with DLBCL with a non-germinal center B-cell immunophenotype. 5-14% of DLBCL cases have been reported with <italic>MYC</italic> translocations (Figure <xref ref-type="fig" rid="F5">5</xref>). <italic>MYC</italic> rearrangement predicts for more aggressive disease, a poorer response to therapy, and is an independent predictor of overall survival in the rituximab era. About 2% of DLBCL cases have <italic>MYC</italic> amplification. Low copy number gains of <italic>MYC</italic> are more common in DLBCL (19-38%) and may be associated with higher levels of mRNA expression [<xref rid="R77" ref-type="bibr">77</xref>]. The presence of <italic>MYC</italic> translocation or amplification is most common in germinal center B-cell tumors that are positive for CD10 and Bcl6, and may be negative for Bcl2 (Table <xref ref-type="table" rid="T1">1</xref>) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R67" ref-type="bibr">67</xref>, <xref rid="R78" ref-type="bibr">78</xref>-<xref rid="R80" ref-type="bibr">80</xref>].</p><p><italic>MYC</italic> rearranged DLBCL may arise <italic>de novo</italic> or may represent at high-grade transformation of a low-grade lymphoma, in which case most commonly disease was follicular lymphoma (FL). In high grade transformation of FL, the <italic>MYC</italic> gene rearrangement is often accompanied by a t(14;18)(q32;q21) chromosome translocation/<italic>BCL2</italic> rearrangement. In the other studies, around 40% of patients, whose tumors carry a dual <italic>MYC</italic>/<italic>BCL2</italic> translocation, were reported to have a history of FL [<xref rid="R81" ref-type="bibr">81</xref>]. However, in other studies, 60-80% cases of DLBCL can be found with <italic>MYC</italic> rearrangements, accompanied by either <italic>BCL2</italic> or <italic>BCL6</italic> rearrangements, without history of low grade disease [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R80" ref-type="bibr">80</xref>, <xref rid="R82" ref-type="bibr">82</xref>, <xref rid="R83" ref-type="bibr">83</xref>].</p><p><italic>MYC</italic> rearrangements in DLBCL can be partnered with <italic>IGH</italic> but, compared with Burkitt lymphoma, are more frequently partnered with the <italic>IGL</italic> or to non-<italic>IG</italic> genes such as <italic>BCL6, BCL11A</italic>, <italic>PAX5</italic> or <italic>ICAROS49</italic> [<xref rid="R84" ref-type="bibr">84</xref>]. <italic>MYC</italic> rearrangements in DLBCL are mainly found in patients &#x0003e; 60 years old with higher clinical stage, higher international prognostic index (IPI) values, and presentation of extranodal disease.</p><p>A <italic>MYC</italic> rearrangement in DLBCL is shown to be associated with inferior outcome in most studies. It is not clear whether the poor prognosis is attributable to the <italic>MYC</italic> rearrangement itself, or due to the fact that 58%-83% of <italic>MYC</italic> translocated DLBCL also had dual or even triple translocations that target <italic>BCL2</italic> and/or <italic>BCL6.</italic> High <italic>MYC</italic> amplifications copy number alterations also have been associated with shorter overall survival [<xref rid="R79" ref-type="bibr">79</xref>].</p><p>Myc protein expression is seen in most cases of DLBCL, but the number of positive cells varies from case to case. Myc protein is highly expressed (&#x0003e;70% of cells) in the nuclei of DLBCL with <italic>MYC</italic> rearrangements or amplification. However, only one third of DLBCL with substantial (&#x0003e;30-40% positive cells) Myc protein expression carry <italic>MYC</italic> gene alterations. This discordance suggests that mechanisms other than gene rearrangements are responsible for elevated protein expression in a considerable proportion of DLBCL cases. Myc overexpression has been associated with inferior prognosis in some studies [<xref rid="R79" ref-type="bibr">79</xref>]. As is the case with <italic>MYC</italic> translocations, Myc overexpression in DLBCL may not be predictive of an inferior prognosis on its own, since there is good evidence that it is the dual deregulation of both Myc and Bcl2 expression that is strongly correlated with shorter survival. Immunohistochemical expression scores using Myc, Bcl2, and possibly Bcl6, are able to identify patients with poor prognosis even within IPI subgroups [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R61" ref-type="bibr">61</xref>, <xref rid="R79" ref-type="bibr">79</xref>].</p></sec><sec id="s7_3"><title>B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</title><p>B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (BCL-U) is a category in the 2008 WHO lymphoma classification. The reason WHO made it become one of B-cell lymphoma classification, is because it presents as a high-grade B-cell lymphoma but cannot be more precisely classified since it does not meet the criteria diagnostic for either BL or DLBCL. It seems likely that most of the tumors in this category are the high-grade end of the spectrum of DLBCL.</p><p>However, BCL-U tend to present in older adults with nodal or extranodal disease and advanced stage of disease. Histopathology of BCL-U is heterogeneous. Some cases closely resemble BL, whereas others are reminiscent of DLBCL. The neoplastic cells express the pan B-cell antigens CD19, CD20, CD79a, and PAX5. The BCL-U that resemble BL usually have an immunophenotype inconsistent with that diagnosis. Immunophenotypic features atypical for BL include the absence of Bcl6 expression, strong Bcl2 expression, and a lower (&#x0003c;95%) Ki-67 proliferation index. The BCL-U that resembles DLBCL may exhibit a BL immunophenotype. CD10 and Bcl6 are expressed. Bcl2 is absent, and the proliferation index is approximately 100%. This group of neoplasms is not associated with EBV infection. Interestingly, 30%-50% of BCL-U cases can carry <italic>MYC</italic> rearrangements (Figure <xref ref-type="fig" rid="F5">5</xref>) [<xref rid="R1" ref-type="bibr">1</xref>].</p><p>In contrast to BL, <italic>MYC</italic> rearrangements in BCL-U are frequently accompanied by translocations involving either <italic>BCL2</italic> and/or <italic>BCL6</italic>. The BCL-U with <italic>MYC</italic> accompanied either by <italic>BCL2</italic> or <italic>BCL6</italic> rearrangement or are referred as &#x0201c;double-hit&#x0201c;lymphoma (DHL). If all three genes are translocated, they are referred to as &#x0201c;triple-hit&#x0201c; (TH) lymphoma. Patients with BCL-U that are also DH or TH lymphomas present with high clinical stage disease, high LDH, frequent extranodal manifestations and bone marrow and central nervous system infiltration. This type of disease had shorter average survival time, usually less than one year [<xref rid="R83" ref-type="bibr">83</xref>, <xref rid="R85" ref-type="bibr">85</xref>-<xref rid="R87" ref-type="bibr">87</xref>]. <italic>MYC</italic> aberrations are also common in BCL-U. The presence of <italic>MYC</italic> aberrations identifies a patient subset that requires more aggressive therapy than R-CHOP. In contrast, <italic>MYC</italic> BCL-U patients responded variably to either R-CHOP or aggressive therapy, and the latter showed no survival advantage [<xref rid="R88" ref-type="bibr">88</xref>].</p><p>Recently, Momose et al sequenced relevant genes that are frequently mutated in BL (<italic>ID3, TCF3</italic>, <italic>CCND3</italic> and <italic>MYC</italic>) and DLBCL (<italic>BCL2</italic>, <italic>EZH2</italic>, <italic>CREBBP</italic>, <italic>EP300</italic>, <italic>MEF2B</italic> and <italic>SGK1</italic>) in 108 aggressive B-cell lymphomas including 31 BL, 24 BCL-U and 53 DLBCL cases, and found that the morphological, immunophenotypic and genetic gray zone between BL and DLBCL is also a gray zone of the mutational spectrum. Thus, it will be difficult to more precisely define molecular subgroups and relevant clinicopathologic entities within this spectrum of aggressive B-cell lymphomas [<xref rid="R89" ref-type="bibr">89</xref>].</p></sec><sec id="s7_4"><title>Double-hit and triple-hit lymphoma (DHL and THL)</title><p>The DH or TH genetic translocation is not restricted to DLBCL or BCL-U. It has also been observed in follicular lymphoma and B-cell lymphoblastic leukemia/lymphoma (TdT<sup>+</sup>). Most DH lymphomas had <italic>MYC</italic> and <italic>BCL2</italic> gene translocations, whereas a small subset has <italic>MYC/BCL6</italic> rearrangements [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R78" ref-type="bibr">78</xref>, <xref rid="R90" ref-type="bibr">90</xref>].</p><p>In Mitelman's database of cytogenetic alterations in cancer, 62% of DH/TH cases had <italic>MYC/BCL2</italic> translocations. 16% of a triple-hit constellation involves <italic>MYC</italic>, <italic>BCL2</italic> and <italic>BCL6</italic>, and 8% of which involve <italic>MYC/BCL6</italic> rearrangement [<xref rid="R91" ref-type="bibr">91</xref>, <xref rid="R92" ref-type="bibr">92</xref>]. More recently, <italic>MYC/BCL6</italic> rearrangement lymphomas have been reported to be more frequently CD10 negative with IRF4/MUM1 positive, and cytogenetically less complex than <italic>MYC/BCL2</italic> rearrangement lymphomas [<xref rid="R93" ref-type="bibr">93</xref>]. In general, in most studies, patients with DH/TH have been reported to run a dismal clinical course [<xref rid="R94" ref-type="bibr">94</xref>].</p></sec><sec id="s7_5"><title>Plasmablastic lymphoma</title><p>Plasmablastic lymphoma (PBL) is a rare aggressive B-cell neoplasm that commonly occurs in patients with immunodeficiency, including HIV-positive adults, posttransplant immunosuppressive therapy, iatrogenic immunosuppression for autoimmune disease, and immunosuppression associated with aging. A subset of patients is not apparently immunodeficient. Patients with these tumors commonly present with extranodal disease, with highest frequency in the head and neck region. The tumor can also affect bone, soft tissue, the gastrointestinal tract, skin, orbit, and the sinonasal cavities. Patients often show advanced stage and an intermediate to-high risk IPI score.</p><p>Characteristic cells of PBL are large, atypical with immunoblastic and/or plasmacytic features, and grow in a diffuse pattern. Mitotic figures are common, with highly proliferation index. The immunophenotype of malignant cells is plasmacytic, characterized by negative results for CD45, CD20, and PAX5 and positive results for CD38, CD138 and MUM1, with variably expression of CD79a and cytoplasmic immunoglobulins. Epstein-Barr virus (EBV) infection with latency I pattern of infection, in about 75% of cases [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R81" ref-type="bibr">81</xref>].</p><p><italic>MYC</italic> translocations are also found in 41-49% of PBL (Figure <xref ref-type="fig" rid="F5">5</xref>). The translocation is commonly present as t(8;14) IGH/<italic>MYC</italic>. Rearrangements of <italic>BCL6</italic> or <italic>BCL2</italic> are rare and PBL does not seem to be part of the &#x0201c;double-hit&#x0201d; spectrum of disease [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R81" ref-type="bibr">81</xref>].</p><p><italic>MYC</italic> activation also seems to play a role in the progression of plasma cell neoplasms particularly from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell myeloma (PCM). This progression is associated with increased levels of Myc expression in the absence of structural alterations of the gene [<xref rid="R95" ref-type="bibr">95</xref>]. <italic>MYC</italic> rearrangements have been found in 0-15% of unselected PCM but in 45% of advanced tumors, particularly in those with extramedullary involvement, and in 65% of PCM cell lines, suggesting that <italic>MYC</italic> structural alterations are associated with progression of the tumors [<xref rid="R71" ref-type="bibr">71</xref>, <xref rid="R96" ref-type="bibr">96</xref>, <xref rid="R97" ref-type="bibr">97</xref>]. Contrary to PBL, <italic>MYC</italic> in PCM is frequently rearranged to non-<italic>IGH</italic> loci. The functional relevance of <italic>MYC</italic> in PCM has been highlighted by the addiction of these cells to <italic>MYC</italic> for survival.</p><p>Some patients with PBL and <italic>MYC</italic> rearrangements showed similar characteristic cells and immunophenotype with PCM [<xref rid="R98" ref-type="bibr">98</xref>]. But both of them can be differed by its association with an immunosuppressed state and presence of EBV infection, that can be found in PBL. Secondary PBL transformation from CLL (chronic lymphocytic leukemia) or FL also can be found <italic>MYC</italic> translocations [<xref rid="R99" ref-type="bibr">99</xref>, <xref rid="R100" ref-type="bibr">100</xref>]. All these observations suggest that <italic>MYC</italic> aberrations do also play a role in the pathogenesis of aggressive lymphoid neoplasms with terminal B-cell differentiation. This finding is remarkable since most aggressive B-cell lymphomas with <italic>MYC</italic> rearrangements have a GC phenotype.</p><p>The terminal B-cell differentiation program is triggered by BLIMP1, a transcription factor highly expressed in PBL. BLIMP1 have several functions such as repressing gene characteristic for mature B-cell such as PAX5 genes, promoting gene that involves differentiation plasma cells such as XBP1 (X-Box binding protein 1), and repressing <italic>MYC</italic> and other controlling cell proliferation and cell growth genes. The presentation of <italic>MYC</italic> in this is maintained by activation of unfolded protein response (UPR), a protective antiapoptotic mechanism which is triggered in the endoplasmic reticulum that helps <italic>MYC</italic> to bypass the pro-apoptotic effect [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R101" ref-type="bibr">101</xref>].</p></sec><sec id="s7_6"><title>Lymphoblastic lymphoma</title><p>Lymphoblastic lymphoma is an aggressive non-Hodgkin lymphoma composed of lymphoblasts and an immature phenotype with expression of TdT and/or CD34 [<xref rid="R65" ref-type="bibr">65</xref>]. It is committed to the B-cell lineage (B-LBL) or T-cell lineage (T-LBL) that accounts for approximately 2% of all lymphomas [<xref rid="R102" ref-type="bibr">102</xref>]. Both T-LBL and B-LBL exist with different clinical phenotypes. T-LBL is much more common than B-LBL in adults, accounting for up to 90% of disease. It is typically seen in adolescents and young adults with a male predominance of nearly 3-fold [<xref rid="R103" ref-type="bibr">103</xref>, <xref rid="R104" ref-type="bibr">104</xref>], mainly presents with a mediastinal mass and shortness of breath due to either compression of the superior vena cava or pericardial or pleural effusions. B-LBL has a more even age distribution with an older predominance [<xref rid="R104" ref-type="bibr">104</xref>, <xref rid="R105" ref-type="bibr">105</xref>]. Compared with T-LBL, B-LBL is less likely to present with bone marrow (<italic>P=</italic>0.03) or mediastinal (<italic>P=</italic>0.04) involvement. Lymphoblastic lymphoma is a chemotherapy-sensitive disease with high initial response rates. However, relapse is common with conventional lymphoma regimens [<xref rid="R106" ref-type="bibr">106</xref>, <xref rid="R107" ref-type="bibr">107</xref>]. One report suggests that B-LBL is more likely to achieve a complete remission (CR) than T-LBL (<italic>P=</italic>0.02), although it is limited by its retrospective nature and small numbers [<xref rid="R105" ref-type="bibr">105</xref>].</p><p>In T-LBL, neoplastic cells are usually TdT positive and variably express CD1a, CD2, CD3, CD4, CD5, CD7 and CD8. The only reliable lineage-specific is surface CD3. In B-LBL, tumour cells are virtually always positive for B cell markers CD19, CD79a and CD22. They are positive for CD10, CD 24, PAX5, and TdT in most cases, while the expression of CD20 and the lineage independent stem cell antigen CD34 is variable and CD45 may be absent. Surface immunoglobulin is usually absent. Most B-LBL have clonal rearrangements of the Ig heavy chain or less frequently of light chain genes. T-cell receptor &#x003b3; or &#x003b2; chain gene rearrangements may be seen in a significant number of cases, but rearrangements are not helpful for lineage assignment [<xref rid="R102" ref-type="bibr">102</xref>].</p><p>In T-LBL, aberrant expression of <italic>MYC</italic> generally occurs downstream of activated NOTCH signaling, which is the major contributor to the pathogenesis of T-lymphoblastic malignancies [<xref rid="R106" ref-type="bibr">106</xref>-<xref rid="R109" ref-type="bibr">109</xref>]. Several retrospective studies showed that patients with PBC-LBL transformation from the preceding FL exhibited c-myc gene aberrations. Another study reports that 7 of 8 cases of transformed PBC-LBL are found with translocations involving 8q24.1 (c-myc gene locus) [<xref rid="R110" ref-type="bibr">110</xref>]. In addition, it is reported that LBL is characterised by concurrent <italic>BCL2</italic> and <italic>MYC</italic> rearrangements with IG gene(s), which may accelerate the onset of LBL tumorigenesis by suppressing Myc-induced apoptosis [<xref rid="R111" ref-type="bibr">111</xref>, <xref rid="R112" ref-type="bibr">112</xref>].</p></sec><sec id="s7_7"><title>Transformed follicular lymphoma</title><p>Transformation of FL to DLBCL or t-FL occurs commonly. This disease has been associated with a poor prognosis. Firstly, these neoplastic cells express pan-B-cells antigens CD20, CD79a, and PAX5. Secondly, Davies et al found that 89% (31/35) of t-FL was of the GCB-DLBCL phenotype in which 80% (28/35) was CD10 positive, while 9% (3/35) were CD10 negative, BCL6 positive and MUM1 negative. Only 9% were classified as non-GCB phenotype with CD10 negative, BCL6 positive and MUM1 positive. Based on their report, no t-FL samples were of the ABC-like phenotype [<xref rid="R113" ref-type="bibr">113</xref>]. Thirdly, transformation of FL can occur in higher proliferation cancer types. These two different pathways are shown by expression of Myc. The transformation of <italic>MYC</italic> in t-FL can appear as the low frequency of translocations (<italic>n</italic> = 6/24 tFL with available FISH data, 25.0%), amplifications (<italic>n</italic> = 13/39, 33.3%) and point mutations reflecting the activity of aberrant somatic hypermutation which were the second commonest tFL-specific lesions gene [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R114" ref-type="bibr">114</xref>].</p><p>Lastly, transformation of FL can present <italic>TP53</italic> loss and mutation, <italic>CDNK2A</italic> loss and <italic>c-REL</italic> amplification. In the Davies et al report, 20% of t-FL patients had <italic>wtTP53</italic> in the antecedent FL. The recurrent alteration of genes involved in the control of cell cycle progression (<italic>CDKN2A/B</italic>, <italic>MYC</italic>) and DNA damage responses (alternative biallelic loss of <italic>TP53</italic> and <italic>CDKN2A</italic>) suggest that loss of genetic stability and deregulated proliferation are critical steps in tFL development. All of these mutations and amplifications caused the increasing proliferation rate of the tumor cells.</p><p>Beside these four characteristics of transformation follicular lymphoma, Lossos et al and Glas et al found increased expression of <italic>LDHA</italic> in this type of tumor. The other genes, such as <italic>HK2</italic>, <italic>CENPF</italic>, <italic>CTPS</italic>, <italic>LDHA</italic>, <italic>P2RY5</italic> and <italic>DNASE1L3</italic> also can be identified in both transformation follicular lymphoma and &#x02018;indolent&#x02019; type FL [<xref rid="R115" ref-type="bibr">115</xref>, <xref rid="R116" ref-type="bibr">116</xref>]. In a study by Gatenby et al, they found expression of the glycolytic genes (<italic>HK2</italic>, <italic>PGM</italic> and <italic>LDHA</italic>) reflects a shift in energy production from oxidative phosphorylation to aerobic glycolysis (the Warburg effect) which provides a complete growth advantage and is the basis of the increased 18F-fluorodeoxyglucose avidity observed by positron emission tomography post-transformation [<xref rid="R113" ref-type="bibr">113</xref>, <xref rid="R117" ref-type="bibr">117</xref>].</p></sec><sec id="s7_8"><title>Mantle cell lymphoma</title><p>Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by t(11;14)(q13;q32)/<italic>CCND1-IGH</italic> and cyclin D1 overexpression [<xref rid="R118" ref-type="bibr">118</xref>, <xref rid="R119" ref-type="bibr">119</xref>]. About 85% of cases are composed of a monotonous infiltrate of small lymphoid cells (centrocytes) without large cells (centroblasts). However, a subset of cases have cytologically aggressive cytologic features, resembling either lymphoblastic lymphoma (blastoid variant) or DLBCL (pleomorphic variant). A subset blastoid variant MCL cases carry <italic>MYC</italic> translocations, often involving <italic>IGH</italic>. These tumors can have BL-like morphologic features and patients have a very poor prognosis [<xref rid="R120" ref-type="bibr">120</xref>]. These tumors also can be considered as a form of DH lymphoma.</p></sec></sec><sec id="s8"><title>TREATMENT IN AGGRESSIVE LYMPHOMA WITH MYC DYSREGULATION</title><p><italic>MYC</italic> has been considered as an undruggable target because the protein structure does not respond to small-molecule inhibition. Wilson suggests two pathways to treat patients with aggressive lymphoma with <italic>MYC</italic> mutation. One approach is through manipulation of the BET bromodomain protein BRD4 and the other idea is through activating the transcription of tristetrapolin (Figure <xref ref-type="fig" rid="F7">7</xref>) [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R121" ref-type="bibr">121</xref>]. The BET Bromodomain has functions in the transcriptional machinery because it can recognize acetylated lysines in its histone tails. Because of that, bromodomain proteins serve as regulatory factors for Myc. In the murine study models of plasma cell myeloma, manipulation of the BET bromodomain protein BRD4 using the compound JQ1 can inhibit Myc gene expression (Table <xref ref-type="table" rid="T3">3</xref>).</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>Illustration of therapeutic intervention approaches targeting <italic>MYC</italic> deregulated oncogenic pathways in aggressive B-cell lymphoma</title><p>(1), In the murine study models of multiple myeloma manipulation of the BET bromodomain protein BRD4 using the compound JQ1. (2), Using a synthetic antisense nucleotide (ASO) to inhibit STAT3. (3), By binding at STAT5-SH2 domains using salicylic acid containing compounds. (4), Using Omo<italic>MYC</italic> to prevent <italic>MYC</italic> binding to promoter E-boxes.</p></caption><graphic xlink:href="oncotarget-06-38591-g007"/></fig><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>New drugs in aggressive lymphoma with MYC dysregulation</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" rowspan="1" colspan="1">Function</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">JQ1</td><td align="center" valign="middle" rowspan="1" colspan="1">inhibit <italic>MYC</italic> gene expression through manipulation BET bromodomain protein BRD4 [<xref rid="R116" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BP-1108 and BP-1075</td><td align="center" valign="middle" rowspan="1" colspan="1">inhibit <italic>MYC</italic> gene expression through STAT5-SH2 binding domain [<xref rid="R117" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZD9150 (ISIS-STAT3Rx or ISIS 481464)</td><td align="center" valign="middle" rowspan="1" colspan="1">inhibit <italic>MYC</italic> gene expression through STAT3 [<xref rid="R117" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Omomyc</td><td align="center" valign="middle" rowspan="1" colspan="1">inhibit <italic>MYC</italic> gene expression by prevent Myc binding to promoter E-boxes [<xref rid="R118" ref-type="bibr">118</xref>]</td></tr></tbody></table></table-wrap><p>BET Bromodomain inhibitors also can induce tumor regression in mouse models of BL, AML, mixed lineage leukemia (MLL) and DLBCL [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R40" ref-type="bibr">40</xref>, <xref rid="R125" ref-type="bibr">125</xref>]. Currently, the BET bromodomain inhibitor I-BET762 (GSK525762) is undergoing clinical phase I/II trial for relapsed/refractory hematologic malignancies patients. CPI-0610 and OTX015, other BET bromodomain inhibitors, are also undergoing phase I clinical trials in patients with hematologic malignancies [<xref rid="R126" ref-type="bibr">126</xref>]. Normal gene expression is tightly controlled by mRNA turnover, regulated by adenylate-uridylate-rich element (AU)-binding proteins (AUBP) that recognize AU-rich elements within transcripts. Tristetrapolin is an AUBP. Lymphomagenesis is promoted by Myc through suppressing the transcription of tristetrapolin. In lymphomas, this transcription is shown to be suppressed which causes no negative feedback in lymphomagenesis process. By restoring the tristetrapolin protein, it can prevent lymphomagenesis and abolishes the malignant transformation. Berg et al suggested another way to inhibit <italic>MYC</italic> over-expression by inhibiting the STAT5-SH2 binding domain [<xref rid="R123" ref-type="bibr">123</xref>]. STAT5, together with STAT1 and STAT3, regulate expression of genes that control the cell cycle (cyclin D1 and D2, and Myc), cell survival (Bcl-xL, Bcl-2, Mcl-1) and angiogenesis (HIF1&#x003b1;, VEGF). Berg et al found that chromone-derived nicotinylhydrazone, the most potent molecule, can disrupt the linkage between 5-carboxyfluorescein-GY (PO3H2) LVLDKW, derived from the erythropoietin (EPO) receptor, and the SH2 domain of STAT5b. This compound also inhibited IFN&#x003b1; stimulated STAT5 tyrosine phosphorylation in lymphoma cells. However, it still need high concentration of the compound (100-200 &#x003bc;M) to achieve the results. Gunning et al. continued the investigation and found more potent compounds to inhibit the STAT5-SH2 domain. Gunning and colleagues identified two salicylic acid based compounds, BP-1108 and BP-1075. These two compounds were potent <italic>in vivo</italic> inhibitors of STAT5 in MV-4-11 and K562 leukemia cell lines. BP-1108 also down-regulated STAT5 dependent genes, including <italic>MYC</italic>, <italic>CCND1, CCND2</italic>, and <italic>MCL1</italic>.</p><p>The other treatment was a synthetic antisense nucleotide (ASO) to inhibit STAT3, designated AZD9150 (ISIS-STAT3Rx or ISIS 481464). The ASO drugs function by binding with messenger RNA (mRNAs) and inhibiting production of disease-causing proteins. The drug already underwent phase I evaluation in six patients with advanced lymphoma (3 DLBCL, 2 Hodgkin lymphoma, 1 MCL) and nine patients with solid tumors. The result showed more than 50% reduction of tumor size in 2/3 DLBCL patients, and no responses in the patients with solid tumors. The drug is undergoing phase 2 clinical trials.</p><p>Savino et al suggested inhibition of Myc actionoperated through omomyc [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R124" ref-type="bibr">124</xref>]. Omomyc is a protein that is able to prevent Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to promoters and transrepression. This function was shown in an animal model of lung adenocarcinoma. The mice continuously received Omomyc and failed to develop lung adenocarcinoma without damaging normal tissues.</p><p><italic>MYC</italic> also up-regulates genes that are involved in glycolysis and glutaminolysis for lymphoma growth. Several preclinical studies reported that inhibition of these enzymes can cause apoptosis and impair <italic>MYC</italic> function. For example, FX11 can elevate ROS production, reduce ATP levels, promote cell death and inhibit progression of <italic>MYC</italic>-dependent lymphoma xenografts through inhibition of lactate dehydrogenase A (LDHA) [<xref rid="R127" ref-type="bibr">127</xref>]. Inhibition of monocaroboxylate transporter by the specific inhibitor AZD3965 and inhibition of glutamine metabolism by the glutamate dehydrogenase 1 (GLUD1) inhibitor EGCG also caused cell apoptosis and repressed lymphoma growth [<xref rid="R128" ref-type="bibr">128</xref>-<xref rid="R130" ref-type="bibr">130</xref>]. Now AZD3965 and EGCG are undergoing phase I clinical trial in DLBCL patients and phase II clinical trial in multiple myeloma patients (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Current treatment strategy in aggressive lymphoma with MYC dysregulation</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Compound name</th><th align="left" valign="middle" rowspan="1" colspan="1">Class</th><th align="left" valign="middle" rowspan="1" colspan="1">Target</th><th align="left" valign="middle" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Flavopiridol</td><td align="left" valign="middle" rowspan="1" colspan="1">CDK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Cdk-9</td><td align="left" valign="middle" rowspan="1" colspan="1">Rahl et al. 2010 [<xref rid="R125" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Purvalanol A</td><td align="left" valign="middle" rowspan="1" colspan="1">CDK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Cdk-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Goga et al. 2007 [<xref rid="R126" ref-type="bibr">126</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SU9516</td><td align="left" valign="middle" rowspan="1" colspan="1">CDK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Cdk-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Yu et al. 2002 [<xref rid="R127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PHA 767491 HCI</td><td align="left" valign="middle" rowspan="1" colspan="1">CDK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Cdk-7 and Cdk-9</td><td align="left" valign="middle" rowspan="1" colspan="1">Montagnoli et al. 2008 [<xref rid="R128" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNS-032</td><td align="left" valign="middle" rowspan="1" colspan="1">CDK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Cdk-2, Cdk-7, and Cdk-9</td><td align="left" valign="middle" rowspan="1" colspan="1">Chen et al. 2009 [<xref rid="R129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JQ1</td><td align="left" valign="middle" rowspan="1" colspan="1">BET bromodomain inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Bromodomain and Extra-Terminal motif (BET) proteins BRD2, BRD3, BRD4 and BRDT</td><td align="left" valign="middle" rowspan="1" colspan="1">Filippakopoulos et al. 2010 [<xref rid="R130" ref-type="bibr">130</xref>] Delmore et al. 2011 [<xref rid="R39" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">I-BET762 (GSK525762)</td><td align="left" valign="middle" rowspan="1" colspan="1">BET bromodomain inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Lipopolysaccharide-inducible gene</td><td align="left" valign="middle" rowspan="1" colspan="1">Chaidos et al. 2015 [<xref rid="R120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPI-0610 and OTX015</td><td align="left" valign="middle" rowspan="1" colspan="1">BET bromodomain inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Bromodomain and Extra-Terminal motif (BET) proteins BRD2, BRD3, BRD4 and BRDT</td><td align="left" valign="middle" rowspan="1" colspan="1">Chaidos et al. 2015 [<xref rid="R120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SGI-1776</td><td align="left" valign="middle" rowspan="1" colspan="1">PIM kinase inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Pim-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Zippo et al. 2007 and 2009 [<xref rid="R131" ref-type="bibr">131</xref>, <xref rid="R132" ref-type="bibr">132</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EPZ004777</td><td align="left" valign="middle" rowspan="1" colspan="1">Dot1 L inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Dot1 L</td><td align="left" valign="middle" rowspan="1" colspan="1">Daigle et al. 2011 [<xref rid="R133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C464</td><td align="left" valign="middle" rowspan="1" colspan="1">p300/CBP ACTfrase inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">p300</td><td align="left" valign="middle" rowspan="1" colspan="1">McMahon et al. 1998 [<xref rid="R134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAHA</td><td align="left" valign="middle" rowspan="1" colspan="1">HDAC inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Histone deacetylases</td><td align="left" valign="middle" rowspan="1" colspan="1">Xu et al. 2005 [<xref rid="R135" ref-type="bibr">135</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Triptolide</td><td align="left" valign="middle" rowspan="1" colspan="1">TFIIH/XPB</td><td align="left" valign="middle" rowspan="1" colspan="1">XPB</td><td align="left" valign="middle" rowspan="1" colspan="1">Titov et al. 2011 [<xref rid="R136" ref-type="bibr">136</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nutlin-3a</td><td align="left" valign="middle" rowspan="1" colspan="1">p53-MDM2 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">p53-MDM-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Felsher et al. 2000 [<xref rid="R137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SB220025</td><td align="left" valign="middle" rowspan="1" colspan="1">MAPK inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">p38</td><td align="left" valign="middle" rowspan="1" colspan="1">Campas et al. 2003 [<xref rid="R138" ref-type="bibr">138</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LY 294002</td><td align="left" valign="middle" rowspan="1" colspan="1">PI3K inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">PI3K</td><td align="left" valign="middle" rowspan="1" colspan="1">Ikezoe et al. 2007 [<xref rid="R139" ref-type="bibr">139</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XAV-939</td><td align="left" valign="middle" rowspan="1" colspan="1">Wnt inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Tankyrase 1,2</td><td align="left" valign="middle" rowspan="1" colspan="1">Distler et al. 2013 [<xref rid="R140" ref-type="bibr">140</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LY-411575</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x003b3;-Secratase inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Notch 1</td><td align="left" valign="middle" rowspan="1" colspan="1">Moellering et al. 2009 [<xref rid="R141" ref-type="bibr">141</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VX-680</td><td align="left" valign="middle" rowspan="1" colspan="1">Aurora kinase inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Aurora kinases</td><td align="left" valign="middle" rowspan="1" colspan="1">Yang et al. 2010 [<xref rid="R142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSC71948</td><td align="left" valign="middle" rowspan="1" colspan="1">BAG1 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">BAG-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Zhang et al. 2011 [<xref rid="R143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ABT263</td><td align="left" valign="middle" rowspan="1" colspan="1">BCL2 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">BCL-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Mason et al. 2008 [<xref rid="R144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VER-155008</td><td align="left" valign="middle" rowspan="1" colspan="1">HSP70 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Hsp70/Hsc70</td><td align="left" valign="middle" rowspan="1" colspan="1">Goloudina et al. 2012 [<xref rid="R145" ref-type="bibr">145</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KW-2478</td><td align="left" valign="middle" rowspan="1" colspan="1">HSP90 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Hsp90</td><td align="left" valign="middle" rowspan="1" colspan="1">Nakashima et al. 2010 [<xref rid="R146" ref-type="bibr">146</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SB 218078</td><td align="left" valign="middle" rowspan="1" colspan="1">Chk1 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Chk-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Murga et al. 2011 [<xref rid="R147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leflunomide</td><td align="left" valign="middle" rowspan="1" colspan="1">DHODH inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">DHODH</td><td align="left" valign="middle" rowspan="1" colspan="1">Liu et al. 2007 [<xref rid="R148" ref-type="bibr">148</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BP-1108, BP-1075</td><td align="left" valign="middle" rowspan="1" colspan="1">STAT5 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">STAT5-SH2 domain</td><td align="left" valign="middle" rowspan="1" colspan="1">Page et al [<xref rid="R149" ref-type="bibr">149</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AZD9150</td><td align="left" valign="middle" rowspan="1" colspan="1">STAT3 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">STAT3</td><td align="left" valign="middle" rowspan="1" colspan="1">Hong et al. 2013 [<xref rid="R150" ref-type="bibr">150</xref>] Furqan et al. 2013 [<xref rid="R117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AZD3965</td><td align="left" valign="middle" rowspan="1" colspan="1">Monocaroboxylate transporter inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Monocaroboxylate transporter</td><td align="left" valign="middle" rowspan="1" colspan="1">Li et al. 2013 [<xref rid="R124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGCG</td><td align="left" valign="middle" rowspan="1" colspan="1">GLUD1 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Glutamate dehydrogenase</td><td align="left" valign="middle" rowspan="1" colspan="1">Qing et al. 2012 [<xref rid="R123" ref-type="bibr">123</xref>]</td></tr></tbody></table></table-wrap><p>In light of poor outcomes with <italic>MYC</italic>-related lymphomas, both intensified chemoimmunotherapy regimens and consolidative stem cell transplantation (SCT) have been evaluated for <italic>MYC</italic> management. Cuccuini et al determined the prognostic significance of <italic>MYC</italic> rearrangement in patients with relapsed/refractory DLBCL prospectively treated by R-ICE or R-DHAP followed by high-dose therapy and autologous stem cell transplantation. The 4-year PFS and OS were significantly lower in the <italic>MYC</italic><sup>+</sup> DLBCL patients than those in the <italic>MYC</italic>
<sup>&#x02212;</sup> DLBCL patients. Type of treatment, R-DHAP or R-ICE had no impact on survivals. Among 161 available tissue specimens, 28 (17%) had <italic>MYC</italic> rearrangements; but, notably, they did not have a higher frequency of early relapse from induction R-CHOP. The lack of a clear benefit from intensification of therapy (with or without SCT) suggests that incorporating novel and targeted agents should be pursued, and several candidate agents are available [<xref rid="R156" ref-type="bibr">156</xref>].</p><p>Currently, combination chemotherapy with R-EPOCH is the only treatment regimen that has the potential to induce complete response in a proportion of DHL patients, although with no overall survival advantage [<xref rid="R157" ref-type="bibr">157</xref>]. Howlett et al compared survival outcomes in DHL patients and found out first-line treatment with R-EPOCH significantly reduced the risk of a progression compared with R-CHOP (relative risk reduction of 34%; <italic>P =</italic> 0.032); however, overall survival (<italic>n</italic> = 374) was not significantly different across treatment approaches. A subset of patients might benefit from intensive induction with/without transplant. Results of these pooled meta-analytic estimates suggest that higher-dose regimens may overcome the factors associated with poor risk in the in DLBCL and FL patients harbouring rearrangements of the <italic>MYC</italic> and <italic>BCL2</italic> genes [<xref rid="R158" ref-type="bibr">158</xref>].</p><p>In a retrospective analysis of 52 patients with <italic>MYC</italic>/<italic>BCL2</italic> double-hit lymphoma, Li et al reported a median overall survival of 18.6 months. The majority of patients in this study received high-intensity chemotherapy regimens (primarily R-hyper-CVAD), while the remaining received a moderate-intensity regimen (R-CHOP). 21% of patients received consolidation with either allogeneic stem cell transplantation or high-dose chemotherapy with autologous stem cell rescue. While elevated LDH, &#x0003e;1 extranodal site and IPI&#x0003e;2 were associated with shorter survival in univariate analysis, neither intensity of treatment regimen nor stem cell transplantation impacted outcomes [<xref rid="R87" ref-type="bibr">87</xref>]. Further investigation into the role of transplant and novel therapy combinations is necessary. The clinical exploration of front-line targeted agents represents a reasonable approach to developing novel treatment options for this patient population [<xref rid="R159" ref-type="bibr">159</xref>-<xref rid="R162" ref-type="bibr">162</xref>].</p><sec id="s8_1"><title>Conclusions and future directions</title><p><italic>MYC</italic> is a transcription factor that influences cell activity including cell growth, cell cycle progression, survival and biosynthesis, or induces apoptosis. <italic>MYC</italic> translocation was first found in Burkitt lymphoma, that carries t(8;14)(q24;q32). <italic>MYC</italic> translocation is not the only feature in Burkitt lymphoma, as mutation in TCF3/ID3 pathway has also been found in this disease. <italic>MYC</italic> translocation can also be found in DLBCL, singly or together with translocations involving <italic>BCL2</italic> or <italic>BCL6</italic>. <italic>MYC</italic> translocations are also involved in other rare aggressive lymphoma types as well as in transformation of low-grade lymphomas. Others have identified several mechanisms to inhibit expression of <italic>MYC</italic>. Firstly, inhibiting Myc expression by manipulating the BET bromodomain protein BRD4. Secondly, inhibiting Myc expression through STAT5-SH2 binding domain or STAT3; and lastly inhibiting Myc expression by preventing Myc binding to promoter E-boxes. However, the clinical utility of strategies targeting <italic>MYC</italic> for patients with lymphoid malignancy remains to be better defined. A complete understanding of the mechanisms by which <italic>MYC</italic> achieves these oncogenic effects remains a daunting challenge. Future researches could include combinations with existing therapies, careful planning of study protocols and the development of unique biomarkers targeted <italic>MYC</italic> signaling pathway. It is also a task that promises to provide critical new insights into the molecular biology of <italic>MYC</italic>-related malignancy.</p></sec></sec></body><back><ack><p>Q.C is the recipient of National Natural Science Foundation of China (NO.81372883, NO.81001052), Science and Technology Planning Project of Guangdong Province, China (2011B031800222), Young Talents Project of Sun Yat-sen University Cancer Center, Young Talents Project of Sun Yat-sen University and the Natural Science Foundation of Guangdong Province, China (8151008901000043). K.H.Y is supported by The University of Texas MD Anderson Cancer Center Lymphoma Moonshot Program, Institutional Research and Development Fund, Institutional Research Grant Award, An MD Anderson Cancer Center Lymphoma SPORE Research Development Program Award, An MD Anderson Cancer Center Myeloma SPORE Research Development Program Award, Gundersen Lutheran Medical Foundation Award. This study was also supported by the National Cancer Institute/National Institutes of Health (R01CA138688, 1RC1CA146299, P50CA136411, and P50CA142509).</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICTS OF INTEREST</bold></p><p>K.H.Y. receives research support from Roche Molecular System, Gilead Science Pharmaceutical, Seattle Genetics, Dai Sanyo Pharmaceutical, Adaptive Biotechnology, and High-Throughput Molecular Diagnostics.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name></person-group><article-title>Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>3884</fpage><lpage>3891</lpage><pub-id pub-id-type="pmid">24009228</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name></person-group><article-title>Reflecting on 25 years with MYC</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>976</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">19029958</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klapproth</surname><given-names>K</given-names></name><name><surname>Wirth</surname><given-names>T</given-names></name></person-group><article-title>Advances in the understanding of MYC-induced lymphomagenesis</article-title><source>Br J Haematol</source><year>2010</year><volume>149</volume><fpage>484</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">20346013</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><article-title>MYC on the path to cancer</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">22464321</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;scher</surname><given-names>B</given-names></name><name><surname>Vervoorts</surname><given-names>J</given-names></name></person-group><article-title>Regulation of gene transcription by the oncoprotein MYC</article-title><source>Gene</source><year>2012</year><volume>494</volume><fpage>145</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">22227497</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquino</surname><given-names>G</given-names></name><name><surname>Marra</surname><given-names>L</given-names></name><name><surname>Cantile</surname><given-names>M</given-names></name><name><surname>De Chiara</surname><given-names>A</given-names></name><name><surname>Liguori</surname><given-names>G</given-names></name><name><surname>Curcio</surname><given-names>MP</given-names></name><name><surname>Sabatino</surname><given-names>R</given-names></name><name><surname>Pannone</surname><given-names>G</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Botti</surname><given-names>G</given-names></name></person-group><article-title>MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas</article-title><source>Infect Agent Cancer</source><year>2013</year><volume>8</volume><fpage>37</fpage><pub-id pub-id-type="pmid">24079473</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Cochran</surname><given-names>BH</given-names></name><name><surname>Stiles</surname><given-names>CD</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group><article-title>Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor</article-title><source>Cell</source><year>1983</year><volume>35</volume><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">6606489</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>C</given-names></name><name><surname>Blanchard</surname><given-names>J</given-names></name><name><surname>Piechaczyk</surname><given-names>M</given-names></name><name><surname>El Sabouty</surname><given-names>S</given-names></name><name><surname>Marty</surname><given-names>L</given-names></name><name><surname>Jeanteur</surname><given-names>P</given-names></name></person-group><article-title>Extreme instability of myc mRNA in normal and transformed human cells</article-title><source>Proc Natl Acad Sci USA</source><year>1984</year><volume>81</volume><fpage>7046</fpage><lpage>7050</lpage><pub-id pub-id-type="pmid">6594679</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hann</surname><given-names>SR</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name></person-group><article-title>Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells</article-title><source>Mol Cell Biol</source><year>1984</year><volume>4</volume><fpage>2486</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">6513926</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hann</surname><given-names>SR</given-names></name></person-group><year>2006</year><article-title>Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function</article-title><source>Semin Cancer Bio</source><year>2006</year><volume>16</volume><fpage>288</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">16938463</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Godinho</surname><given-names>SA</given-names></name><name><surname>Pellerin</surname><given-names>A</given-names></name><name><surname>K&#x000f6;chert</surname><given-names>K</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name><name><surname>de Albor&#x000e1;n</surname><given-names>IM</given-names></name><name><surname>Janz</surname><given-names>M</given-names></name><name><surname>Rodig</surname><given-names>S</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><article-title>The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">23001146</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Pinkert</surname><given-names>C</given-names></name><name><surname>Corcoran</surname><given-names>L</given-names></name><name><surname>Alexander</surname><given-names>W</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Palmiter</surname><given-names>R</given-names></name><name><surname>Brinster</surname><given-names>R</given-names></name></person-group><article-title>The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice</article-title><source>Nature</source><year>1984</year><volume>318</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">3906410</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Ludkovski</surname><given-names>O</given-names></name><name><surname>Ben-Neriah</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>R</given-names></name><name><surname>Steidl</surname><given-names>C</given-names></name><name><surname>Dyer</surname><given-names>MJ</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Kuruvilla</surname><given-names>J</given-names></name><name><surname>Klasa</surname><given-names>R</given-names></name></person-group><article-title>Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>2273</fpage><lpage>2279</lpage><pub-id pub-id-type="pmid">19597184</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uribesalgo</surname><given-names>I</given-names></name><name><surname>Buschbeck</surname><given-names>M</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>A</given-names></name><name><surname>Teichmann</surname><given-names>S</given-names></name><name><surname>Demajo</surname><given-names>S</given-names></name><name><surname>Kuebler</surname><given-names>B</given-names></name><name><surname>Nomded&#x000e9;u</surname><given-names>JF</given-names></name><name><surname>Mart&#x000ed;n-Caballero</surname><given-names>J</given-names></name><name><surname>Roma</surname><given-names>G</given-names></name><name><surname>Benitah</surname><given-names>SA</given-names></name></person-group><article-title>E-box-independent regulation of transcription and differentiation by MYC</article-title><source>Nat Cell Biol</source><year>2011</year><volume>13</volume><fpage>1443</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">22020439</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>S</given-names></name><name><surname>Soucek</surname><given-names>L</given-names></name><name><surname>Evan</surname><given-names>G</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><article-title>c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>5707</fpage><lpage>5711</lpage><pub-id pub-id-type="pmid">12944920</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Herbst</surname><given-names>A</given-names></name><name><surname>Tworkowski</surname><given-names>KA</given-names></name><name><surname>Salghetti</surname><given-names>SE</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><article-title>Skp2 regulates Myc protein stability and activity</article-title><source>Mol Cell</source><year>2003</year><volume>11</volume><fpage>1177</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">12769843</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gargano</surname><given-names>B</given-names></name><name><surname>Amente</surname><given-names>S</given-names></name><name><surname>Majello</surname><given-names>B</given-names></name><name><surname>Lania</surname><given-names>L</given-names></name></person-group><article-title>P-TEFb is a crucial co-factor for Myc transactivation</article-title><source>Cell Cycle</source><year>2007</year><volume>6</volume><fpage>2031</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">17700062</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psathas</surname><given-names>JN</given-names></name><name><surname>Doonan</surname><given-names>PJ</given-names></name><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Freedman</surname><given-names>BD</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name></person-group><article-title>The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>4220</fpage><lpage>4229</lpage><pub-id pub-id-type="pmid">24169826</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>T-C</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>Y-S</given-names></name><name><surname>Wentzel</surname><given-names>EA</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>West</surname><given-names>KM</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name></person-group><article-title>Widespread microRNA repression by Myc contributes to tumorigenesis</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18066065</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>A</given-names></name><name><surname>Be&#x000e0;</surname><given-names>S</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>V</given-names></name><name><surname>Prieto</surname><given-names>M</given-names></name><name><surname>Salaverria</surname><given-names>I</given-names></name><name><surname>Jares</surname><given-names>P</given-names></name><name><surname>Hartmann</surname><given-names>E</given-names></name><name><surname>Mozos</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Guillermo</surname><given-names>A</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name></person-group><article-title>MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>7071</fpage><lpage>7078</lpage><pub-id pub-id-type="pmid">19690137</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Fiskus</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Lwin</surname><given-names>T</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>JC</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>Marquez</surname><given-names>VE</given-names></name></person-group><article-title>Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>506</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">23079660</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotillo</surname><given-names>E</given-names></name><name><surname>Laver</surname><given-names>T</given-names></name><name><surname>Mellert</surname><given-names>H</given-names></name><name><surname>Schelter</surname><given-names>J</given-names></name><name><surname>Cleary</surname><given-names>M</given-names></name><name><surname>McMahon</surname><given-names>S</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name></person-group><article-title>Myc overexpression brings out unexpected antiapoptotic effects of miR-34a</article-title><source>Oncogene</source><year>2011</year><volume>30</volume><fpage>2587</fpage><lpage>2594</lpage><pub-id pub-id-type="pmid">21297663</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>MJ</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name></person-group><article-title>MicroRNAs and the cell cycle</article-title><source>Biochim Biophys Acta</source><year>2011</year><volume>1812</volume><fpage>592</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">21315819</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>PS</given-names></name><name><surname>Casey</surname><given-names>SC</given-names></name><name><surname>Dill</surname><given-names>DL</given-names></name><name><surname>Felsher</surname><given-names>DW</given-names></name></person-group><article-title>MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state</article-title><source>Cancer cell</source><year>2014</year><volume>26</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">25117713</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>MS</given-names></name><name><surname>Hart</surname><given-names>JR</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><article-title>A brave new MYC-amplified world</article-title><source>Aging (Albany NY)</source><year>2015</year><volume>7</volume><fpage>459</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">26186937</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><article-title>Long non-coding RNAs: insights into functions</article-title><source>Nat Rev Genet</source><year>2009</year><volume>10</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">19188922</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>KV</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><article-title>The rise of regulatory RNA</article-title><source>Nat Rev Genet</source><year>2014</year><volume>15</volume><fpage>423</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">24776770</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Lwin</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Moscinski</surname><given-names>L</given-names></name><name><surname>Dalton</surname><given-names>W</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name><name><surname>Wright</surname><given-names>K</given-names></name><name><surname>Sotomayor</surname><given-names>E</given-names></name></person-group><article-title>Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>3002</fpage><lpage>3008</lpage><pub-id pub-id-type="pmid">22002311</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlewood</surname><given-names>TD</given-names></name><name><surname>Kreuzaler</surname><given-names>P</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>All things to all people</article-title><source>Cell</source><year>2012</year><volume>151</volume><fpage>11</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">23021211</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Cui</surname><given-names>K</given-names></name><name><surname>Yamane</surname><given-names>A</given-names></name><name><surname>Resch</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Casellas</surname><given-names>R</given-names></name></person-group><article-title>c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells</article-title><source>Cell</source><year>2012</year><volume>151</volume><fpage>68</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">23021216</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lov&#x000e9;n</surname><given-names>J</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><article-title>Transcriptional amplification in tumor cells with elevated c-Myc</article-title><source>Cell</source><year>2012</year><volume>151</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">23021215</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DM</given-names></name><name><surname>Thomas</surname><given-names>SD</given-names></name><name><surname>Islam</surname><given-names>A</given-names></name><name><surname>Muench</surname><given-names>D</given-names></name><name><surname>Sedoris</surname><given-names>K</given-names></name></person-group><article-title>c-Myc and cancer metabolism</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>5546</fpage><lpage>5553</lpage><pub-id pub-id-type="pmid">23071356</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><article-title>P53 and prognosis: new insights and further complexity</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15652475</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>L</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Paik</surname><given-names>JH</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Kearney</surname><given-names>JF</given-names></name><name><surname>Otipoby</surname><given-names>KL</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><article-title>PI3 kinase signals BCR-dependent mature B cell survival</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>573</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">19879843</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sewastianik</surname><given-names>T</given-names></name><name><surname>Prochorec-Sobieszek</surname><given-names>M</given-names></name><name><surname>Chapuy</surname><given-names>B</given-names></name><name><surname>Juszczynski</surname><given-names>P</given-names></name></person-group><article-title>MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications</article-title><source>Biochim Biophys Acta</source><year>2014</year><volume>1846</volume><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">25199984</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>CJ</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>Cinalli</surname><given-names>RM</given-names></name><name><surname>Master</surname><given-names>SR</given-names></name><name><surname>Chodosh</surname><given-names>LA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor</article-title><source>Genes Dev</source><year>2003</year><volume>17</volume><fpage>1841</fpage><lpage>1854</lpage><pub-id pub-id-type="pmid">12869584</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>T</given-names></name></person-group><article-title>Small-molecule modulators of c-Myc/Max and Max/Max interactions</article-title><source>Curr Top Microbiol Immunol</source><year>2011</year><volume>348</volume><fpage>139</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">20680803</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albihn</surname><given-names>A</given-names></name><name><surname>Johnsen</surname><given-names>JI</given-names></name><name><surname>Henriksson</surname><given-names>MA</given-names></name></person-group><article-title>MYC in oncogenesis and as a target for cancer therapies</article-title><source>Adv Cancer Res</source><year>2010</year><volume>107</volume><fpage>163</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">20399964</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name></person-group><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">21889194</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>JA</given-names></name><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sims</surname><given-names>RJ</given-names></name></person-group><article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="pmid">21949397</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lov&#x000e9;n</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>HA</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>320</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">23582323</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Sola</surname><given-names>D</given-names></name><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Ying</surname><given-names>CY</given-names></name><name><surname>Phan</surname><given-names>RT</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name></person-group><article-title>The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">23001145</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>RM</given-names></name><name><surname>Ceribelli</surname><given-names>M</given-names></name><name><surname>Jhavar</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Shaffer</surname><given-names>AL</given-names></name><name><surname>Hodson</surname><given-names>DJ</given-names></name><name><surname>Buras</surname><given-names>E</given-names></name></person-group><article-title>Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">22885699</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramiro</surname><given-names>AR</given-names></name><name><surname>Jankovic</surname><given-names>M</given-names></name><name><surname>Eisenreich</surname><given-names>T</given-names></name><name><surname>Difilippantonio</surname><given-names>S</given-names></name><name><surname>Chen-Kiang</surname><given-names>S</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>AID is required for c-myc/IgH chromosome translocations <italic>in vivo</italic></article-title><source>Cell</source><year>2004</year><volume>118</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">15315756</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>V</given-names></name><name><surname>Butzhammer</surname><given-names>P</given-names></name><name><surname>Hirsch</surname><given-names>B</given-names></name><name><surname>Hecht</surname><given-names>J</given-names></name><name><surname>G&#x000fc;tgemann</surname><given-names>I</given-names></name><name><surname>Ehlers</surname><given-names>A</given-names></name><name><surname>Lenze</surname><given-names>D</given-names></name><name><surname>Oker</surname><given-names>E</given-names></name><name><surname>Sommerfeld</surname><given-names>A</given-names></name><name><surname>von der Wall</surname><given-names>E</given-names></name></person-group><article-title>Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e26837</fpage><pub-id pub-id-type="pmid">22102868</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzankov</surname><given-names>A</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Visco</surname><given-names>C</given-names></name><name><surname>Dirnhofer</surname><given-names>S</given-names></name><name><surname>Gisin</surname><given-names>N</given-names></name><name><surname>Dybkaer</surname><given-names>K</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Bhagat</surname><given-names>G</given-names></name><name><surname>Richards</surname><given-names>KL</given-names></name></person-group><article-title>Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP</article-title><source>Mod Pathol</source><year>2014</year><volume>27</volume><fpage>958</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">24336156</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>TX</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>JZ</given-names></name><name><surname>Miao</surname><given-names>KR</given-names></name><name><surname>Liang</surname><given-names>JH</given-names></name><name><surname>Gong</surname><given-names>QX</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>ZH</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name></person-group><article-title>MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>18374</fpage><lpage>18388</lpage><pub-id pub-id-type="pmid">26158410</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casc&#x000f3;n</surname><given-names>A</given-names></name><name><surname>Robledo</surname><given-names>M</given-names></name></person-group><article-title>MAX and MYC: a heritable breakup</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>3119</fpage><lpage>3124</lpage><pub-id pub-id-type="pmid">22706201</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucek</surname><given-names>L</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>The ups and downs of Myc biology</article-title><source>Curr Opin Genet Dev</source><year>2010</year><volume>20</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19962879</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestdagh</surname><given-names>P</given-names></name><name><surname>Bostrom</surname><given-names>AK</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Fredlund</surname><given-names>E</given-names></name><name><surname>Van Peer</surname><given-names>G</given-names></name><name><surname>De Antonellis</surname><given-names>P</given-names></name><name><surname>von Stedingk</surname><given-names>K</given-names></name><name><surname>Ghesquiere</surname><given-names>B</given-names></name><name><surname>Schulte</surname><given-names>S</given-names></name><name><surname>Dews</surname><given-names>M</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name><name><surname>Schulte</surname><given-names>JH</given-names></name><name><surname>Zollo</surname><given-names>M</given-names></name><name><surname>Schramm</surname><given-names>A</given-names></name><name><surname>Gevaert</surname><given-names>K</given-names></name><name><surname>Axelson</surname><given-names>H</given-names></name><etal/></person-group><article-title>The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma</article-title><source>Mol Cell</source><year>2010</year><volume>40</volume><fpage>762</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">21145484</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>Pear</surname><given-names>W</given-names></name><name><surname>Nowell</surname><given-names>PC</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name></person-group><article-title>Chronic myelogenous leukemia: laboratory diagnosis and monitoring</article-title><source>Genes Chromosomes Cancer</source><year>2001</year><volume>32</volume><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">11550277</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>CD</given-names></name><name><surname>Gusenleitner</surname><given-names>D</given-names></name><name><surname>Chapuy</surname><given-names>B</given-names></name><name><surname>Kovach</surname><given-names>AE</given-names></name><name><surname>Kluk</surname><given-names>MJ</given-names></name><name><surname>Sun</surname><given-names>HH</given-names></name><name><surname>Crossland</surname><given-names>RE</given-names></name><name><surname>Bacon</surname><given-names>CM</given-names></name><name><surname>Rand</surname><given-names>V</given-names></name><name><surname>Dal Cin</surname><given-names>P</given-names></name><name><surname>Le</surname><given-names>LP</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Sohani</surname><given-names>AR</given-names></name><name><surname>Shipp</surname><given-names>MA</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name></person-group><article-title>Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens</article-title><source>J Mol Diagn</source><year>2015</year><volume>17</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">25468432</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haralambieva</surname><given-names>E</given-names></name><name><surname>Schuuring</surname><given-names>E</given-names></name><name><surname>Rosati</surname><given-names>S</given-names></name><name><surname>van Noesel</surname><given-names>C</given-names></name><name><surname>Jansen</surname><given-names>P</given-names></name><name><surname>Appel</surname><given-names>I</given-names></name><name><surname>Guikema</surname><given-names>J</given-names></name><name><surname>Wabinga</surname><given-names>H</given-names></name><name><surname>Bleggi Torres</surname><given-names>L Fernando</given-names></name><name><surname>Lam</surname><given-names>K</given-names></name></person-group><article-title>Interphase fluorescence <italic>in situ</italic> hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>40</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15034863</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurel</surname><given-names>B</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Koh</surname><given-names>CM</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Van Dang</surname><given-names>C</given-names></name><name><surname>Hicks</surname><given-names>JL</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Cornish</surname><given-names>TC</given-names></name><name><surname>Sutcliffe</surname><given-names>S</given-names></name></person-group><article-title>Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis</article-title><source>Mod Pathol</source><year>2008</year><volume>21</volume><fpage>1156</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">18567993</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardim</surname><given-names>DL</given-names></name><name><surname>Conley</surname><given-names>A</given-names></name><name><surname>Subbiah</surname><given-names>V</given-names></name></person-group><article-title>Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities</article-title><source>Orphanet J Rare Dis</source><year>2013</year><volume>8</volume><fpage>112</fpage><pub-id pub-id-type="pmid">23895135</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louro</surname><given-names>ID</given-names></name><name><surname>Bailey</surname><given-names>EC</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>South</surname><given-names>LS</given-names></name><name><surname>McKie-Bell</surname><given-names>PR</given-names></name><name><surname>Yoder</surname><given-names>BK</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Hill</surname><given-names>AE</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Ruppert</surname><given-names>JM</given-names></name></person-group><article-title>Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>5867</fpage><lpage>5873</lpage><pub-id pub-id-type="pmid">12384550</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>SB</given-names></name><name><surname>Turner</surname><given-names>EH</given-names></name><name><surname>Robertson</surname><given-names>PD</given-names></name><name><surname>Flygare</surname><given-names>SD</given-names></name><name><surname>Bigham</surname><given-names>AW</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Shaffer</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Bamshad</surname><given-names>M</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><article-title>Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>272</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">19684571</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petricoin</surname><given-names>EF</given-names></name><name><surname>Zoon</surname><given-names>KC</given-names></name><name><surname>Kohn</surname><given-names>EC</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name></person-group><article-title>Clinical proteomics: translating benchside promise into bedside reality</article-title><source>Nat Rev Drug Discov</source><year>2002</year><volume>1</volume><fpage>683</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">12209149</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzinova</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>T</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name></person-group><article-title>Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">20442643</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>TM</given-names></name><name><surname>Nielsen</surname><given-names>O</given-names></name><name><surname>de Stricker</surname><given-names>K</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Moller</surname><given-names>MB</given-names></name></person-group><article-title>High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma</article-title><source>Am J Surg Pathol</source><year>2012</year><volume>36</volume><fpage>612</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">22314191</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Slack</surname><given-names>GW</given-names></name><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Ben-Neriah</surname><given-names>S</given-names></name><name><surname>Rogic</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>DW</given-names></name><name><surname>Tan</surname><given-names>KL</given-names></name><name><surname>Steidl</surname><given-names>C</given-names></name><name><surname>Sehn</surname><given-names>LH</given-names></name></person-group><article-title>Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>3452</fpage><lpage>3459</lpage><pub-id pub-id-type="pmid">22851565</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>TM</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Visco</surname><given-names>C</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Go</surname><given-names>RS</given-names></name><name><surname>Nielsen</surname><given-names>O</given-names></name><name><surname>Gadeberg</surname><given-names>OV</given-names></name><name><surname>Mourits-Andersen</surname><given-names>T</given-names></name><name><surname>Frederiksen</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>LM</given-names></name><name><surname>Moller</surname><given-names>MB</given-names></name></person-group><article-title>Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>3460</fpage><lpage>3467</lpage><pub-id pub-id-type="pmid">22665537</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Tzankov</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Balasubramanyam</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>WM</given-names></name><name><surname>Visco</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Miranda</surname><given-names>RN</given-names></name><name><surname>Montes-Moreno</surname><given-names>S</given-names></name><name><surname>Dybkaer</surname><given-names>K</given-names></name><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Zu</surname><given-names>Y</given-names></name><name><surname>Bhagat</surname><given-names>G</given-names></name><etal/></person-group><article-title>MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4021</fpage><lpage>4031</lpage><pub-id pub-id-type="pmid">23449635</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu-Monette</surname><given-names>Z</given-names></name><name><surname>Dabaja</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>M</given-names></name><name><surname>Manyam</surname><given-names>G</given-names></name><name><surname>Tzankov</surname><given-names>A</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Carlo</surname><given-names>V</given-names></name><name><surname>Karen</surname><given-names>D</given-names></name><name><surname>Lihui</surname><given-names>Y</given-names></name><name><surname>April</surname><given-names>C</given-names></name><name><surname>Attilio</surname><given-names>O</given-names></name><name><surname>Youli</surname><given-names>Z</given-names></name><name><surname>Govind</surname><given-names>B</given-names></name><name><surname>Kristy</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Clinical features, tumor biology and prognosis associated with MYC rearrangement and overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP</article-title><source>Mod Pathol</source><year>2015</year></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name></person-group><article-title>Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification</article-title><source>ASH Education Program Book</source><year>2011</year><volume>2011</volume><fpage>506</fpage><lpage>514</lpage></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boerma</surname><given-names>E</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>Baudis</surname><given-names>M</given-names></name></person-group><article-title>Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">18923440</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haralambieva</surname><given-names>E</given-names></name><name><surname>Boerma</surname><given-names>E-J</given-names></name><name><surname>van Imhoff</surname><given-names>GW</given-names></name><name><surname>Rosati</surname><given-names>S</given-names></name><name><surname>Schuuring</surname><given-names>E</given-names></name><name><surname>M&#x000fc;ller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name></person-group><article-title>Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma</article-title><source>Am J Surg Pathol</source><year>2005</year><volume>29</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">16006805</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Bentink</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Wessendorf</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>T</given-names></name><name><surname>Bernd</surname><given-names>H</given-names></name><name><surname>Cogliatti</surname><given-names>S</given-names></name><name><surname>Dierlamm</surname><given-names>J</given-names></name><name><surname>Feller</surname><given-names>A</given-names></name></person-group><article-title>Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe a biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2419</fpage><lpage>2430</lpage><pub-id pub-id-type="pmid">16760442</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niitsu</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>I</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name></person-group><article-title>Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t (14; 18) and 8q24/c-MYC translocations</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>777</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">19151788</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>P</given-names></name><name><surname>Bastard</surname><given-names>C</given-names></name><name><surname>Maingonnat</surname><given-names>C</given-names></name><name><surname>Jardin</surname><given-names>F</given-names></name><name><surname>Maisonneuve</surname><given-names>C</given-names></name><name><surname>Courel</surname><given-names>MN</given-names></name><name><surname>Ruminy</surname><given-names>P</given-names></name><name><surname>Picquenot</surname><given-names>JM</given-names></name><name><surname>Tilly</surname><given-names>H</given-names></name></person-group><article-title>Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">17230227</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valera</surname><given-names>A</given-names></name><name><surname>Balagu&#x000e9;</surname><given-names>O</given-names></name><name><surname>Colomo</surname><given-names>L</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Delabie</surname><given-names>J</given-names></name><name><surname>Taddesse-Heath</surname><given-names>L</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name></person-group><article-title>IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>1686</fpage><pub-id pub-id-type="pmid">20962620</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onnis</surname><given-names>A</given-names></name><name><surname>De Falco</surname><given-names>G</given-names></name><name><surname>Antonicelli</surname><given-names>G</given-names></name><name><surname>Onorati</surname><given-names>M</given-names></name><name><surname>Bellan</surname><given-names>C</given-names></name><name><surname>Sherman</surname><given-names>O</given-names></name><name><surname>Sayed</surname><given-names>S</given-names></name><name><surname>Leoncini</surname><given-names>L</given-names></name></person-group><article-title>Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e12960</fpage><pub-id pub-id-type="pmid">20930934</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salaverria</surname><given-names>I</given-names></name><name><surname>Martin-Guerrero</surname><given-names>I</given-names></name><name><surname>Wagener</surname><given-names>R</given-names></name><name><surname>Kreuz</surname><given-names>M</given-names></name><name><surname>Kohler</surname><given-names>CW</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Pienkowska-Grela</surname><given-names>B</given-names></name><name><surname>Adam</surname><given-names>P</given-names></name><name><surname>Burkhardt</surname><given-names>B</given-names></name><name><surname>Claviez</surname><given-names>A</given-names></name><name><surname>Damm-Welk</surname><given-names>C</given-names></name><name><surname>Drexler</surname><given-names>HG</given-names></name><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Kuppers</surname><given-names>R</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><etal/></person-group><article-title>A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma</article-title><source>Blood</source><year>2014</year><volume>123</volume><fpage>1187</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">24398325</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Bentink</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Wessendorf</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>TF</given-names></name><name><surname>Bernd</surname><given-names>HW</given-names></name><name><surname>Cogliatti</surname><given-names>SB</given-names></name><name><surname>Dierlamm</surname><given-names>J</given-names></name><name><surname>Feller</surname><given-names>AC</given-names></name><name><surname>Hansmann</surname><given-names>ML</given-names></name><name><surname>Haralambieva</surname><given-names>E</given-names></name><name><surname>Harder</surname><given-names>L</given-names></name><name><surname>Hasenclever</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Lenze</surname><given-names>D</given-names></name><etal/></person-group><article-title>A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2419</fpage><lpage>2430</lpage><pub-id pub-id-type="pmid">16760442</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>SS</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>GW</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Kluin</surname><given-names>P</given-names></name><name><surname>Boerma</surname><given-names>EJ</given-names></name><name><surname>Greiner</surname><given-names>TC</given-names></name><name><surname>Weisenburger</surname><given-names>DD</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Muller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Delabie</surname><given-names>J</given-names></name><name><surname>Rimsza</surname><given-names>LM</given-names></name><name><surname>Braziel</surname><given-names>RM</given-names></name><name><surname>Grogan</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Molecular diagnosis of Burkitt's lymphoma</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2431</fpage><lpage>2442</lpage><pub-id pub-id-type="pmid">16760443</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dybkaer</surname><given-names>K</given-names></name><name><surname>Bogsted</surname><given-names>M</given-names></name><name><surname>Falgreen</surname><given-names>S</given-names></name><name><surname>Bodker</surname><given-names>JS</given-names></name><name><surname>Kjeldsen</surname><given-names>MK</given-names></name><name><surname>Schmitz</surname><given-names>A</given-names></name><name><surname>Bilgrau</surname><given-names>AE</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Bergkvist</surname><given-names>KS</given-names></name><name><surname>Laursen</surname><given-names>MB</given-names></name><name><surname>Rodrigo-Domingo</surname><given-names>M</given-names></name><name><surname>Marques</surname><given-names>SC</given-names></name><name><surname>Rasmussen</surname><given-names>SB</given-names></name><name><surname>Nyegaard</surname><given-names>M</given-names></name><name><surname>Gaihede</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>1379</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">25800755</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasik</surname><given-names>CJ</given-names></name><name><surname>Nitta</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Mosher</surname><given-names>CH</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Tubbs</surname><given-names>RR</given-names></name><name><surname>Unger</surname><given-names>JM</given-names></name><name><surname>Brooks</surname><given-names>TA</given-names></name><name><surname>Persky</surname><given-names>DO</given-names></name><name><surname>Wilkinson</surname><given-names>ST</given-names></name></person-group><article-title>Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma</article-title><source>Haematologica</source><year>2010</year><volume>95</volume><fpage>597</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">20378577</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Trifonov</surname><given-names>V</given-names></name><name><surname>Fabbri</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Chiarenza</surname><given-names>A</given-names></name><name><surname>Wells</surname><given-names>VA</given-names></name><name><surname>Grunn</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>M</given-names></name><name><surname>Elliot</surname><given-names>O</given-names></name></person-group><article-title>Analysis of the coding genome of diffuse large B-cell lymphoma</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><fpage>830</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">21804550</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valera</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Guillermo</surname><given-names>A</given-names></name><name><surname>Cardesa-Salzmann</surname><given-names>T</given-names></name><name><surname>Climent</surname><given-names>F</given-names></name><name><surname>Gonz&#x000e1;lez-Barca</surname><given-names>E</given-names></name><name><surname>Mercadal</surname><given-names>S</given-names></name><name><surname>Espinosa</surname><given-names>&#x000cd;</given-names></name><name><surname>Novelli</surname><given-names>S</given-names></name><name><surname>Briones</surname><given-names>J</given-names></name><name><surname>Mate</surname><given-names>JL</given-names></name></person-group><article-title>MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy</article-title><source>Haematologica</source><year>2013</year><volume>98</volume><fpage>1554</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">23716551</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>H</given-names></name><name><surname>Ziepert</surname><given-names>M</given-names></name><name><surname>Becher</surname><given-names>C</given-names></name><name><surname>Barth</surname><given-names>TF</given-names></name><name><surname>Bernd</surname><given-names>H-W</given-names></name><name><surname>Feller</surname><given-names>AC</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Hansmann</surname><given-names>M-L</given-names></name></person-group><article-title>MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>2253</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">23335369</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>N</given-names></name></person-group><article-title>BCL2 and MYC dual-hit lymphoma/leukemia</article-title><source>J Clin Exp Hematop</source><year>2011</year><volume>51</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">21628855</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Ben-Neriah</surname><given-names>S</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Sehn</surname><given-names>LH</given-names></name><name><surname>Farinha</surname><given-names>P</given-names></name><name><surname>Horsman</surname><given-names>DE</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name></person-group><article-title>MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>3533</fpage><lpage>3537</lpage><pub-id pub-id-type="pmid">19704118</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrans</surname><given-names>S</given-names></name><name><surname>Crouch</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>K</given-names></name><name><surname>Owen</surname><given-names>R</given-names></name><name><surname>Patmore</surname><given-names>R</given-names></name><name><surname>Roman</surname><given-names>E</given-names></name><name><surname>Jack</surname><given-names>A</given-names></name></person-group><article-title>Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>3360</fpage><lpage>3365</lpage><pub-id pub-id-type="pmid">20498406</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>P</given-names></name><name><surname>Bastard</surname><given-names>C</given-names></name><name><surname>Maingonnat</surname><given-names>C</given-names></name><name><surname>Jardin</surname><given-names>F</given-names></name><name><surname>Maisonneuve</surname><given-names>C</given-names></name><name><surname>Courel</surname><given-names>M</given-names></name><name><surname>Ruminy</surname><given-names>P</given-names></name><name><surname>Picquenot</surname><given-names>J</given-names></name><name><surname>Tilly</surname><given-names>H</given-names></name></person-group><article-title>Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">17230227</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Gouill</surname><given-names>S</given-names></name><name><surname>Talmant</surname><given-names>P</given-names></name><name><surname>Touzeau</surname><given-names>C</given-names></name><name><surname>Moreau</surname><given-names>A</given-names></name><name><surname>Garand</surname><given-names>R</given-names></name><name><surname>Juge-Morineau</surname><given-names>N</given-names></name><name><surname>Gaillard</surname><given-names>F</given-names></name><name><surname>Gastinne</surname><given-names>T</given-names></name><name><surname>Milpied</surname><given-names>N</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name></person-group><article-title>The clinical presentation and prognosis of diffuse large B-cell lymphoma with t (14; 18) and 8q24/c-MYC rearrangement</article-title><source>Haematologica</source><year>2007</year><volume>92</volume><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">18024371</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Kolman</surname><given-names>OK</given-names></name><name><surname>Chen</surname><given-names>Y-B</given-names></name><name><surname>Hsu</surname><given-names>JJ</given-names></name><name><surname>Ackerman</surname><given-names>AM</given-names></name><name><surname>Dal Cin</surname><given-names>P</given-names></name><name><surname>Ferry</surname><given-names>JA</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Zukerberg</surname><given-names>LR</given-names></name></person-group><article-title>B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>327</fpage><pub-id pub-id-type="pmid">20118770</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Fayad</surname><given-names>LE</given-names></name><name><surname>Lennon</surname><given-names>PA</given-names></name><name><surname>Miranda</surname><given-names>RN</given-names></name><name><surname>Yin</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name></person-group><article-title>B-cell lymphomas with MYC/8q24 rearrangements and IGH@ BCL2/t (14; 18)(q32; q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">22002575</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Dickason</surname><given-names>TJ</given-names></name><name><surname>Fayad</surname><given-names>LE</given-names></name><name><surname>Lennon</surname><given-names>PA</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Routbort</surname><given-names>MJ</given-names></name><name><surname>Miranda</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name></person-group><article-title>Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>1566</fpage><lpage>1573</lpage><pub-id pub-id-type="pmid">21882178</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momose</surname><given-names>S</given-names></name><name><surname>Weissbach</surname><given-names>S</given-names></name><name><surname>Pischimarov</surname><given-names>J</given-names></name><name><surname>Nedeva</surname><given-names>T</given-names></name><name><surname>Bach</surname><given-names>E</given-names></name><name><surname>Rudelius</surname><given-names>M</given-names></name><name><surname>Geissinger</surname><given-names>E</given-names></name><name><surname>Staiger</surname><given-names>AM</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name></person-group><article-title>The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum</article-title><source>Leukemia</source><year>2015</year><volume>29</volume><fpage>1789</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">25673238</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Seegmiller</surname><given-names>AC</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Miranda</surname><given-names>RN</given-names></name><name><surname>Bhagavathi</surname><given-names>S</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name></person-group><article-title>B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas</article-title><source>Mod Pathol</source><year>2015</year><volume>28</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">25103070</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><source>Mitelman database of chromosome aberrations and gene fusions in cancer</source><comment>Mitelman F, Johansson B, Mertens F, editors</comment><year>2012</year></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aukema</surname><given-names>SM</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Schuuring</surname><given-names>E</given-names></name><name><surname>van Imhoff</surname><given-names>GW</given-names></name><name><surname>Kluin-Nelemans</surname><given-names>HC</given-names></name><name><surname>Boerma</surname><given-names>E-J</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name></person-group><article-title>Double-hit B-cell lymphomas</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>2319</fpage><lpage>2331</lpage><pub-id pub-id-type="pmid">21119107</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>RK</given-names></name><name><surname>Sathanoori</surname><given-names>M</given-names></name><name><surname>Van Oss</surname><given-names>SB</given-names></name><name><surname>Swerdlow</surname><given-names>SH</given-names></name></person-group><article-title>Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">23348205</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name></person-group><article-title>Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases</article-title><source>Am J Surg Pathol</source><year>2015</year><volume>39</volume><fpage>1132</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">25828391</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehl</surname><given-names>WM</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name></person-group><article-title>Molecular pathogenesis of multiple myeloma and its premalignant precursor</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>3456</fpage><lpage>3463</lpage><pub-id pub-id-type="pmid">23023717</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avet-Loiseau</surname><given-names>H</given-names></name><name><surname>Gerson</surname><given-names>F</given-names></name><name><surname>Magrangeas</surname><given-names>F</given-names></name><name><surname>Minvielle</surname><given-names>S</given-names></name><name><surname>Harousseau</surname><given-names>J-L</given-names></name><name><surname>Bataille</surname><given-names>R</given-names></name></person-group><article-title>Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>3082</fpage><lpage>3086</lpage><pub-id pub-id-type="pmid">11698294</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrea</surname><given-names>A</given-names></name><name><surname>Martelli</surname><given-names>ML</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Roschke</surname><given-names>A</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Shaughnessy</surname><given-names>JD</given-names></name><name><surname>Sawyer</surname><given-names>JR</given-names></name><name><surname>Kuehl</surname><given-names>WM</given-names></name></person-group><article-title>Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors</article-title><source>Genes Chromosomes Cancer</source><year>2008</year><volume>47</volume><fpage>573</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">18381641</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taddesse-Heath</surname><given-names>L</given-names></name><name><surname>Meloni-Ehrig</surname><given-names>A</given-names></name><name><surname>Scheerle</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>JC</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name></person-group><article-title>Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features</article-title><source>Mod Pathol</source><year>2010</year><volume>23</volume><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">20348882</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouansafi</surname><given-names>I</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name><name><surname>Nie</surname><given-names>K</given-names></name><name><surname>Mathew</surname><given-names>S</given-names></name><name><surname>Bhanji</surname><given-names>R</given-names></name><name><surname>Hoda</surname><given-names>R</given-names></name><name><surname>Arabadjief</surname><given-names>M</given-names></name><name><surname>Knowles</surname><given-names>D</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name></person-group><article-title>Transformation of follicular lymphoma to plasmablastic lymphoma with c-myc gene rearrangement</article-title><source>Am J Clin Pathol</source><year>2010</year><volume>134</volume><fpage>972</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">21088162</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>D</given-names></name><name><surname>Valera</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>NS</given-names></name><name><surname>Villegas</surname><given-names>LFS</given-names></name><name><surname>Gonzalez-Farre</surname><given-names>B</given-names></name><name><surname>Sole</surname><given-names>C</given-names></name><name><surname>Gine</surname><given-names>E</given-names></name><name><surname>Lopez-Guillermo</surname><given-names>A</given-names></name><name><surname>Roue</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>S</given-names></name></person-group><article-title>Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>272</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">23282972</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>LS</given-names></name><name><surname>Cunningham</surname><given-names>JT</given-names></name><name><surname>Datta</surname><given-names>T</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Tameire</surname><given-names>F</given-names></name><name><surname>Lehman</surname><given-names>SL</given-names></name><name><surname>Qiu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cerniglia</surname><given-names>G</given-names></name><name><surname>Bi</surname><given-names>M</given-names></name></person-group><article-title>ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>4621</fpage><pub-id pub-id-type="pmid">23143306</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortelazzo</surname><given-names>S</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Ferreri</surname><given-names>AJ</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name></person-group><article-title>Lymphoblastic lymphoma</article-title><source>Crit Rev Oncol/Hematol</source><year>2011</year><volume>79</volume><fpage>330</fpage><lpage>343</lpage></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathwani</surname><given-names>BN</given-names></name><name><surname>Diamond</surname><given-names>LW</given-names></name><name><surname>Winberg</surname><given-names>CD</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Bearman</surname><given-names>RM</given-names></name><name><surname>Glick</surname><given-names>JH</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name><name><surname>Gams</surname><given-names>RA</given-names></name><name><surname>Nissen</surname><given-names>NI</given-names></name><name><surname>Rappaport</surname><given-names>H</given-names></name></person-group><article-title>Lymphoblastic lymphoma: a clinicopathologic study of 95 patients</article-title><source>Cancer</source><year>1981</year><volume>48</volume><fpage>2347</fpage><lpage>2357</lpage><pub-id pub-id-type="pmid">6895347</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groves</surname><given-names>FD</given-names></name><name><surname>Linet</surname><given-names>MS</given-names></name><name><surname>Travis</surname><given-names>LB</given-names></name><name><surname>Devesa</surname><given-names>SS</given-names></name></person-group><article-title>Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1240</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">10922409</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soslow</surname><given-names>RA</given-names></name><name><surname>Baergen</surname><given-names>RN</given-names></name><name><surname>Warnke</surname><given-names>RA</given-names></name></person-group><article-title>B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>2648</fpage><lpage>2654</lpage><pub-id pub-id-type="pmid">10375114</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>AP</given-names></name><name><surname>Millholland</surname><given-names>JM</given-names></name><name><surname>Yashiro-Ohtani</surname><given-names>Y</given-names></name><name><surname>Arcangeli</surname><given-names>ML</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Wai</surname><given-names>C</given-names></name><name><surname>del Bianco</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>CG</given-names></name><name><surname>Sai</surname><given-names>H</given-names></name><name><surname>Tobias</surname><given-names>J</given-names></name></person-group><article-title>c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma</article-title><source>Genes Dev</source><year>2006</year><volume>20</volume><fpage>2096</fpage><lpage>2109</lpage><pub-id pub-id-type="pmid">16847353</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>AP</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Silverman</surname><given-names>LB</given-names></name><name><surname>Sanchez-Irizarry</surname><given-names>C</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name></person-group><article-title>Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia</article-title><source>Science</source><year>2004</year><volume>306</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">15472075</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Neuberg</surname><given-names>DS</given-names></name><name><surname>Staunton</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Huard</surname><given-names>C</given-names></name><name><surname>Raimondi</surname><given-names>SC</given-names></name><name><surname>Behm</surname><given-names>FG</given-names></name><name><surname>Pui</surname><given-names>C-H</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><article-title>Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia</article-title><source>Cancer cell</source><year>2002</year><volume>1</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">12086890</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pear</surname><given-names>WS</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Soffer</surname><given-names>B</given-names></name><name><surname>Sklar</surname><given-names>J</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>2283</fpage><lpage>2291</lpage><pub-id pub-id-type="pmid">8642337</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Eickhoff</surname><given-names>JC</given-names></name><name><surname>Sanger</surname><given-names>WG</given-names></name><name><surname>Aoun</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name></person-group><article-title>Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event</article-title><source>Am J Clin Pathol</source><year>2008</year><volume>129</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">18089500</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Bath</surname><given-names>ML</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name></person-group><article-title>Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2</article-title><source>Nature</source><year>1990</year><volume>348</volume><fpage>331</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">2250704</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Stachura</surname><given-names>DL</given-names></name><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sanda</surname><given-names>T</given-names></name><name><surname>Jette</surname><given-names>CA</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name><name><surname>Neuberg</surname><given-names>DS</given-names></name><name><surname>Langenau</surname><given-names>DM</given-names></name></person-group><article-title>T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation</article-title><source>Cancer cell</source><year>2010</year><volume>18</volume><fpage>353</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">20951945</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>AJ</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Last</surname><given-names>KW</given-names></name><name><surname>Weisenburger</surname><given-names>DD</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Delabie</surname><given-names>J</given-names></name><name><surname>Braziel</surname><given-names>RM</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name></person-group><article-title>Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms</article-title><source>Br J Haematol</source><year>2007</year><volume>136</volume><fpage>286</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">17278262</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Khiabanian</surname><given-names>H</given-names></name><name><surname>Fangazio</surname><given-names>M</given-names></name><name><surname>Vasishtha</surname><given-names>M</given-names></name><name><surname>Messina</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>AB</given-names></name><name><surname>Ouillette</surname><given-names>P</given-names></name><name><surname>Trifonov</surname><given-names>V</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Tabbo</surname><given-names>F</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Murty</surname><given-names>VV</given-names></name><name><surname>Bhagat</surname><given-names>G</given-names></name><name><surname>Gaidano</surname><given-names>G</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name><etal/></person-group><article-title>Genetics of follicular lymphoma transformation</article-title><source>Cell Rep</source><year>2014</year><volume>6</volume><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">24388756</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lossos</surname><given-names>IS</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Warnke</surname><given-names>R</given-names></name><name><surname>Thorstenson</surname><given-names>Y</given-names></name><name><surname>Oefner</surname><given-names>PJ</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>8886</fpage><lpage>8891</lpage><pub-id pub-id-type="pmid">12077300</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glas</surname><given-names>AM</given-names></name><name><surname>Kersten</surname><given-names>MJ</given-names></name><name><surname>Delahaye</surname><given-names>LJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Kibbelaar</surname><given-names>RE</given-names></name><name><surname>Velds</surname><given-names>A</given-names></name><name><surname>Wessels</surname><given-names>LF</given-names></name><name><surname>Joosten</surname><given-names>P</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>van Krieken</surname><given-names>JH</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name></person-group><article-title>Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">15345589</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Gillies</surname><given-names>RJ</given-names></name></person-group><article-title>Why do cancers have high aerobic glycolysis?</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>891</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15516961</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>HM</given-names></name><name><surname>McDonnell</surname><given-names>TJ</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Leventaki</surname><given-names>V</given-names></name><name><surname>O'Connor</surname><given-names>SL</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name></person-group><article-title>Characterization of 4 mantle cell lymphoma cell lines</article-title><source>Arch Pathol Lab Med</source><year>2003</year><volume>127</volume><fpage>424</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">12683869</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name></person-group><article-title>Pathologic diagnosis of mantle cell lymphoma</article-title><source>Clin Lymphoma</source><year>2000</year><volume>1</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">11707830</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Sanger</surname><given-names>W</given-names></name><name><surname>Onciu</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Schlette</surname><given-names>EJ</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name></person-group><article-title>Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features</article-title><source>Mod Pathol</source><year>2002</year><volume>15</volume><fpage>1266</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">12481006</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>M-M</given-names></name></person-group><article-title>The role of human bromodomains in chromatin biology and gene transcription</article-title><source>Curr Opin Drug Discov Devel</source><year>2009</year><volume>12</volume><fpage>659</fpage></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>WH</given-names></name></person-group><article-title>Treatment strategies for aggressive lymphomas: what works?</article-title><source>ASH Education Program Book</source><year>2013</year><volume>2013</volume><fpage>584</fpage><lpage>590</lpage></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furqan</surname><given-names>M</given-names></name><name><surname>Akinleye</surname><given-names>A</given-names></name><name><surname>Mukhi</surname><given-names>N</given-names></name><name><surname>Mittal</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>STAT inhibitors for cancer therapy</article-title><source>J Hematol Oncol</source><year>2013</year><volume>6</volume><fpage>90</fpage><pub-id pub-id-type="pmid">24308725</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savino</surname><given-names>M</given-names></name><name><surname>Annibali</surname><given-names>D</given-names></name><name><surname>Carucci</surname><given-names>N</given-names></name><name><surname>Favuzzi</surname><given-names>E</given-names></name><name><surname>Cole</surname><given-names>MD</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Soucek</surname><given-names>L</given-names></name><name><surname>Nasi</surname><given-names>S</given-names></name></person-group><article-title>The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e22284</fpage><pub-id pub-id-type="pmid">21811581</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>CJ</given-names></name><name><surname>Kopp</surname><given-names>N</given-names></name><name><surname>Bird</surname><given-names>L</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Bowman</surname><given-names>T</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name></person-group><article-title>BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>2843</fpage><lpage>2852</lpage><pub-id pub-id-type="pmid">22904298</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaidos</surname><given-names>A</given-names></name><name><surname>Caputo</surname><given-names>V</given-names></name><name><surname>Karadimitris</surname><given-names>A</given-names></name></person-group><article-title>Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence</article-title><source>Ther Adv Hematol</source><year>2015</year><volume>6</volume><fpage>128</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">26137204</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>CR</given-names></name><name><surname>Gouw</surname><given-names>AM</given-names></name><name><surname>Dinavahi</surname><given-names>R</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Deck</surname><given-names>LM</given-names></name><name><surname>Royer</surname><given-names>RE</given-names></name><name><surname>Vander Jagt</surname><given-names>DL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><article-title>Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression</article-title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><fpage>2037</fpage><lpage>2042</lpage><pub-id pub-id-type="pmid">20133848</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahl</surname><given-names>ML</given-names></name><name><surname>Owen</surname><given-names>JA</given-names></name><name><surname>Burd</surname><given-names>R</given-names></name><name><surname>Herlands</surname><given-names>RA</given-names></name><name><surname>Nogami</surname><given-names>SS</given-names></name><name><surname>Rodeck</surname><given-names>U</given-names></name><name><surname>Berd</surname><given-names>D</given-names></name><name><surname>Leeper</surname><given-names>DB</given-names></name><name><surname>Owen</surname><given-names>CS</given-names></name></person-group><article-title>Regulation of Intracellular pH in Human Melanoma: Potential Therapeutic Implications</article-title><source>Mol Cancer Ther</source><year>2002</year><volume>1</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">12479222</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Vu</surname><given-names>A</given-names></name><name><surname>Skuli</surname><given-names>N</given-names></name><name><surname>Walton</surname><given-names>ZE</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Mayes</surname><given-names>PA</given-names></name><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name></person-group><article-title>ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>631</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">23153536</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><article-title>Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>5835</fpage><lpage>5841</lpage><pub-id pub-id-type="pmid">23897900</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Seila</surname><given-names>AC</given-names></name><name><surname>Flynn</surname><given-names>RA</given-names></name><name><surname>McCuine</surname><given-names>S</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><article-title>c-Myc regulates transcriptional pause release</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>432</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">20434984</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goga</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Tward</surname><given-names>AD</given-names></name><name><surname>Morgan</surname><given-names>DO</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC</article-title><source>Nat Med</source><year>2007</year><volume>13</volume><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">17589519</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Lane</surname><given-names>ME</given-names></name><name><surname>Wadler</surname><given-names>S</given-names></name></person-group><article-title>SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells</article-title><source>Biochem Pharmacol</source><year>2002</year><volume>64</volume><fpage>1091</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">12234612</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnoli</surname><given-names>A</given-names></name><name><surname>Valsasina</surname><given-names>B</given-names></name><name><surname>Croci</surname><given-names>V</given-names></name><name><surname>Menichincheri</surname><given-names>M</given-names></name><name><surname>Rainoldi</surname><given-names>S</given-names></name><name><surname>Marchesi</surname><given-names>V</given-names></name><name><surname>Tibolla</surname><given-names>M</given-names></name><name><surname>Tenca</surname><given-names>P</given-names></name><name><surname>Brotherton</surname><given-names>D</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Patton</surname><given-names>V</given-names></name><name><surname>Alzani</surname><given-names>R</given-names></name><name><surname>Ciavolella</surname><given-names>A</given-names></name><name><surname>Sola</surname><given-names>F</given-names></name><name><surname>Molinari</surname><given-names>A</given-names></name><name><surname>Volpi</surname><given-names>D</given-names></name><etal/></person-group><article-title>A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity</article-title><source>Nat Chem Biol</source><year>2008</year><volume>4</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">18469809</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Chubb</surname><given-names>S</given-names></name><name><surname>Hawtin</surname><given-names>RE</given-names></name><name><surname>Fox</surname><given-names>JA</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Gandhi</surname><given-names>V</given-names></name><name><surname>Plunkett</surname><given-names>W</given-names></name></person-group><article-title>Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>4637</fpage><lpage>4645</lpage><pub-id pub-id-type="pmid">19234140</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Picaud</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>WB</given-names></name><name><surname>Fedorov</surname><given-names>O</given-names></name><name><surname>Morse</surname><given-names>EM</given-names></name><name><surname>Keates</surname><given-names>T</given-names></name><name><surname>Hickman</surname><given-names>TT</given-names></name><name><surname>Felletar</surname><given-names>I</given-names></name></person-group><article-title>Selective inhibition of BET bromodomains</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">20871596</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zippo</surname><given-names>A</given-names></name><name><surname>De Robertis</surname><given-names>A</given-names></name><name><surname>Serafini</surname><given-names>R</given-names></name><name><surname>Oliviero</surname><given-names>S</given-names></name></person-group><article-title>PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation</article-title><source>Nat Cell Biol</source><year>2007</year><volume>9</volume><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">17643117</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zippo</surname><given-names>A</given-names></name><name><surname>Serafini</surname><given-names>R</given-names></name><name><surname>Rocchigiani</surname><given-names>M</given-names></name><name><surname>Pennacchini</surname><given-names>S</given-names></name><name><surname>Krepelova</surname><given-names>A</given-names></name><name><surname>Oliviero</surname><given-names>S</given-names></name></person-group><article-title>Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation</article-title><source>Cell</source><year>2009</year><volume>138</volume><fpage>1122</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">19766566</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname><given-names>SR</given-names></name><name><surname>Olhava</surname><given-names>EJ</given-names></name><name><surname>Therkelsen</surname><given-names>CA</given-names></name><name><surname>Majer</surname><given-names>CR</given-names></name><name><surname>Sneeringer</surname><given-names>CJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Johnston</surname><given-names>LD</given-names></name><name><surname>Scott</surname><given-names>MP</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name></person-group><article-title>Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">21741596</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>SB</given-names></name><name><surname>Van Buskirk</surname><given-names>HA</given-names></name><name><surname>Dugan</surname><given-names>KA</given-names></name><name><surname>Copeland</surname><given-names>TD</given-names></name><name><surname>Cole</surname><given-names>MD</given-names></name></person-group><article-title>The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins</article-title><source>Cell</source><year>1998</year><volume>94</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">9708738</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Voelter-Mahlknecht</surname><given-names>S</given-names></name><name><surname>Mahlknecht</surname><given-names>U</given-names></name></person-group><article-title>The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines</article-title><source>Int J Mol Med</source><year>2005</year><volume>15</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">15583844</pub-id></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titov</surname><given-names>DV</given-names></name><name><surname>Gilman</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>QL</given-names></name><name><surname>Bhat</surname><given-names>S</given-names></name><name><surname>Low</surname><given-names>WK</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Smeaton</surname><given-names>M</given-names></name><name><surname>Demain</surname><given-names>AL</given-names></name><name><surname>Miller</surname><given-names>PS</given-names></name><name><surname>Kugel</surname><given-names>JF</given-names></name><name><surname>Goodrich</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>JO</given-names></name></person-group><article-title>XPB, a subunit of TFIIH, is a target of the natural product triptolide</article-title><source>Nat Chem Biol</source><year>2011</year><volume>7</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">21278739</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felsher</surname><given-names>DW</given-names></name><name><surname>Zetterberg</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Tlsty</surname><given-names>T</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>10544</fpage><lpage>10548</lpage><pub-id pub-id-type="pmid">10962037</pub-id></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campas</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>JM</given-names></name><name><surname>Santidri&#x000e1;n</surname><given-names>AF</given-names></name><name><surname>Barrag&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Bellosillo</surname><given-names>B</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name></person-group><article-title>Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>3674</fpage><lpage>3680</lpage><pub-id pub-id-type="pmid">12522004</pub-id></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikezoe</surname><given-names>T</given-names></name><name><surname>Nishioka</surname><given-names>C</given-names></name><name><surname>Bandobashi</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Kuwayama</surname><given-names>Y</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name></person-group><article-title>Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells</article-title><source>Leuk Res</source><year>2007</year><volume>31</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">17007924</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Distler</surname><given-names>A</given-names></name><name><surname>Deloch</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Dees</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>NY</given-names></name><name><surname>Palumbo-Zerr</surname><given-names>K</given-names></name><name><surname>Beyer</surname><given-names>C</given-names></name><name><surname>Weidemann</surname><given-names>A</given-names></name><name><surname>Distler</surname><given-names>O</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Distler</surname><given-names>JH</given-names></name></person-group><article-title>Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1575</fpage><lpage>1580</lpage><pub-id pub-id-type="pmid">23148305</pub-id></element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moellering</surname><given-names>RE</given-names></name><name><surname>Cornejo</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>TN</given-names></name><name><surname>Del Bianco</surname><given-names>C</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Verdine</surname><given-names>GL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><article-title>Direct inhibition of the NOTCH transcription factor complex</article-title><source>Nature</source><year>2009</year><volume>462</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">19907488</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Goga</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Yuneva</surname><given-names>M</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>13836</fpage><lpage>13841</lpage><pub-id pub-id-type="pmid">20643922</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Pfeiffer</surname><given-names>HK</given-names></name><name><surname>Mellert</surname><given-names>HS</given-names></name><name><surname>Stanek</surname><given-names>TJ</given-names></name><name><surname>Sussman</surname><given-names>RT</given-names></name><name><surname>Kumari</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Rigoutsos</surname><given-names>I</given-names></name><name><surname>Thomas-Tikhonenko</surname><given-names>A</given-names></name><name><surname>Seidel</surname><given-names>HE</given-names></name><name><surname>Chodosh</surname><given-names>LA</given-names></name><name><surname>Packham</surname><given-names>G</given-names></name><name><surname>Baserga</surname><given-names>R</given-names></name><name><surname>McMahon</surname><given-names>SB</given-names></name></person-group><article-title>Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC</article-title><source>Mol Cell Biol</source><year>2011</year><volume>31</volume><fpage>5037</fpage><lpage>5045</lpage><pub-id pub-id-type="pmid">21986497</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>KD</given-names></name><name><surname>Vandenberg</surname><given-names>CJ</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Wei</surname><given-names>AH</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>DC</given-names></name><name><surname>Roberts</surname><given-names>AW</given-names></name></person-group><article-title><italic>In vivo</italic> efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>17961</fpage><lpage>17966</lpage><pub-id pub-id-type="pmid">19004807</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goloudina</surname><given-names>AR</given-names></name><name><surname>Demidov</surname><given-names>ON</given-names></name><name><surname>Garrido</surname><given-names>C</given-names></name></person-group><article-title>Inhibition of HSP70: a challenging anti-cancer strategy</article-title><source>Cancer Lett</source><year>2012</year><volume>325</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">22750096</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Tagaya</surname><given-names>H</given-names></name><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>Y</given-names></name><name><surname>Akinaga</surname><given-names>S</given-names></name><name><surname>Soga</surname><given-names>S</given-names></name><name><surname>Shiotsu</surname><given-names>Y</given-names></name></person-group><article-title>New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>2792</fpage><lpage>2802</lpage><pub-id pub-id-type="pmid">20406843</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murga</surname><given-names>M</given-names></name><name><surname>Campaner</surname><given-names>S</given-names></name><name><surname>Lopez-Contreras</surname><given-names>AJ</given-names></name><name><surname>Toledo</surname><given-names>LI</given-names></name><name><surname>Soria</surname><given-names>R</given-names></name><name><surname>Montana</surname><given-names>MF</given-names></name><name><surname>D'Artista</surname><given-names>L</given-names></name><name><surname>Schleker</surname><given-names>T</given-names></name><name><surname>Guerra</surname><given-names>C</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Amati</surname><given-names>B</given-names></name><name><surname>Fernandez-Capetillo</surname><given-names>O</given-names></name></person-group><article-title>Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors</article-title><source>Nat Struct Mol Biol</source><year>2011</year><volume>18</volume><fpage>1331</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">22120667</pub-id></element-citation></ref><ref id="R154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Mandl-Weber</surname><given-names>S</given-names></name><name><surname>Volkl</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>C</given-names></name><name><surname>Bumeder</surname><given-names>I</given-names></name><name><surname>Oduncu</surname><given-names>F</given-names></name><name><surname>Schmidmaier</surname><given-names>R</given-names></name></person-group><article-title>Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells</article-title><source>Mol Cancer Ther</source><year>2009</year><volume>8</volume><fpage>366</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">19174558</pub-id></element-citation></ref><ref id="R155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>BD</given-names></name><name><surname>Khoury</surname><given-names>H</given-names></name><name><surname>Laister</surname><given-names>RC</given-names></name><name><surname>Fletcher</surname><given-names>S</given-names></name><name><surname>Vellozo</surname><given-names>M</given-names></name><name><surname>Manzoli</surname><given-names>A</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Turkson</surname><given-names>J</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Gunning</surname><given-names>PT</given-names></name></person-group><article-title>Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity</article-title><source>J Med Chem</source><year>2012</year><volume>55</volume><fpage>1047</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">22148584</pub-id></element-citation></ref><ref id="R156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuccuini</surname><given-names>W</given-names></name><name><surname>Briere</surname><given-names>J</given-names></name><name><surname>Mounier</surname><given-names>N</given-names></name><name><surname>Voelker</surname><given-names>H-U</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Sundstrom</surname><given-names>C</given-names></name><name><surname>Cogliatti</surname><given-names>S</given-names></name><name><surname>Hirchaud</surname><given-names>E</given-names></name><name><surname>Ysebaert</surname><given-names>L</given-names></name><name><surname>Bron</surname><given-names>D</given-names></name></person-group><article-title>MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>4619</fpage><lpage>4624</lpage><pub-id pub-id-type="pmid">22408263</pub-id></element-citation></ref><ref id="R157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrich</surname><given-names>AM</given-names></name><name><surname>Gandhi</surname><given-names>M</given-names></name><name><surname>Jovanovic</surname><given-names>B</given-names></name><name><surname>Castillo</surname><given-names>JJ</given-names></name><name><surname>Rajguru</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>DT</given-names></name><name><surname>Shah</surname><given-names>KA</given-names></name><name><surname>Whyman</surname><given-names>JD</given-names></name><name><surname>Lansigan</surname><given-names>F</given-names></name><name><surname>Hernandez-Ilizaliturri</surname><given-names>FJ</given-names></name><name><surname>Lee</surname><given-names>LX</given-names></name><name><surname>Barta</surname><given-names>SK</given-names></name><name><surname>Melinamani</surname><given-names>S</given-names></name><name><surname>Karmali</surname><given-names>R</given-names></name><name><surname>Adeimy</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>2354</fpage><lpage>2361</lpage><pub-id pub-id-type="pmid">25161267</pub-id></element-citation></ref><ref id="R158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>C</given-names></name><name><surname>Snedecor</surname><given-names>SJ</given-names></name><name><surname>Landsburg</surname><given-names>DJ</given-names></name><name><surname>Svoboda</surname><given-names>J</given-names></name><name><surname>Chong</surname><given-names>EA</given-names></name><name><surname>Schuster</surname><given-names>SJ</given-names></name><name><surname>Nasta</surname><given-names>SD</given-names></name><name><surname>Feldman</surname><given-names>T</given-names></name><name><surname>Rago</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>KM</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Goy</surname><given-names>A</given-names></name><name><surname>Mato</surname><given-names>A</given-names></name></person-group><article-title>Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis</article-title><source>Br J Haematol</source><year>2015</year><volume>170</volume><fpage>504</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">25907897</pub-id></element-citation></ref><ref id="R159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunleavy</surname><given-names>K</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Shovlin</surname><given-names>M</given-names></name><name><surname>Pack</surname><given-names>S</given-names></name><name><surname>Steinberg</surname><given-names>SM</given-names></name><name><surname>Lai</surname><given-names>CE</given-names></name><name><surname>Grant</surname><given-names>C</given-names></name><name><surname>Hsi</surname><given-names>ED</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name></person-group><article-title>Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>3029</fpage><lpage>3029</lpage></element-citation></ref><ref id="R160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oki</surname><given-names>Y</given-names></name><name><surname>Noorani</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Neelapu</surname><given-names>SS</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>MA</given-names></name><name><surname>Hagemeister</surname><given-names>FB</given-names></name><name><surname>Fowler</surname><given-names>N</given-names></name></person-group><article-title>Double hit lymphoma: the MD Anderson Cancer Center clinical experience</article-title><source>Br J Haematol</source><year>2014</year><volume>166</volume><fpage>891</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">24943107</pub-id></element-citation></ref><ref id="R161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testoni</surname><given-names>M</given-names></name><name><surname>Zucca</surname><given-names>E</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name></person-group><article-title>Genetic lesions in diffuse large B-cell lymphomas</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><fpage>1069</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">25605746</pub-id></element-citation></ref><ref id="R162"><label>162</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name></person-group><chapter-title>Diffuse large B-cell lymphoma</chapter-title><person-group person-group-type="editor"><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>LM</given-names></name><name><surname>Foucar</surname><given-names>K</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name></person-group><source>Neoplastic Hematopathology</source><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>Lippincott Willaims &#x00026; Wilkins</publisher-name><year>2014</year><fpage>502</fpage><lpage>565</lpage></element-citation></ref></ref-list></back></article>